412 results
Search Results
2. The Influence of Inflammatory and Nutritional Status on the Long-Term Outcomes in Advanced Stage Ovarian Cancer.
- Author
-
Bacalbasa, Nicolae, Petrea, Sorin, Gaspar, Bogdan, Pop, Lucian, Varlas, Valentin, Hasegan, Adrian, Gorecki, Gabriel, Martac, Cristina, Stoian, Marilena, Zgura, Anca, and Balescu, Irina
- Subjects
RECEIVER operating characteristic curves ,T-test (Statistics) ,OVARIAN tumors ,LOGISTIC regression analysis ,PREOPERATIVE care ,CYTOREDUCTIVE surgery ,TREATMENT effectiveness ,RETROSPECTIVE studies ,GLASGOW Coma Scale ,DESCRIPTIVE statistics ,HOSPITALS ,CHI-squared test ,KAPLAN-Meier estimator ,NUTRITIONAL status ,INFLAMMATION ,TUMOR classification ,DATA analysis software ,BIOMARKERS ,C-reactive protein ,SERUM albumin ,OVERALL survival ,PROPORTIONAL hazards models - Abstract
Simple Summary: Achieving improved rates of overall survival remains a significant challenge in advanced-stage ovarian cancer; even if complete debulking is achieved, certain patients report poor results in terms of survival. Therefore, the aim of this paper is to investigate new prognostic markers that could point out which cases could benefit most from debulking surgery and which ones should be rather submitted to neoadjuvant therapies followed by debulking surgery. Background: Despite improving surgical techniques and achieving more often complete debulking procedures, certain patients with advanced-stage ovarian cancer still have a very poor prognosis. The aim of the current paper is to investigate whether inflammatory and nutritional status can predict the long-term outcomes of ovarian cancer patients. Methods: A retrospective analysis of 57 cases diagnosed with advanced-stage ovarian cancer submitted to surgery as first intent therapy was carried out. In all cases, the preoperative status was determined by calculating the CRP/albumin ratio, as well as the Glasgow score, the modified Glasgow score and the prognostic nutritional index. Results: Patients presenting higher values of the CRP/albumin ratio, with a higher Glasgow score, modified Glasgow score and prognostic nutritional index (PNI), were more frequently associated with incomplete debulking surgery, a higher peritoneal carcinomatosis index and poorer overall survival (20 months versus 9 months for the CRP/albumin ratio p = 0.011, 42 versus 27 versus 12 months for the Glasgow score p = 0.042, 50 versus 19 versus 12 months for the modified Glasgow score, p = 0.001, and 54 months versus 21 months, p = 0.011 for the prognostic nutritional index). Conclusions: A strong relationship between the nutritional and inflammatory status in advanced-stage ovarian cancer seems to exist. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
- Author
-
Giraudo, Alexandre, Sabatier, Renaud, Rousseau, Frederique, De Nonneville, Alexandre, Gonçalves, Anthony, Cecile, Maud, Braticevic, Cecile, Viret, Frederic, Seguin, Lorene, Kfoury, Maria, Naudet, Dorothée, Hamon, Marie, and Tassy, Louis
- Subjects
PROTEIN kinase inhibitors ,BREAST tumors ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,MEDLINE ,ODDS ratio ,DRUG efficacy ,QUALITY of life ,TUMOR classification ,DATA analysis software ,ONLINE information services ,CONFIDENCE intervals ,OLD age - Abstract
Simple Summary: This position paper aims to address specific clinical questions regarding the use of cyclin-dependent kinase 4/6 inhibitors in elderly patients with early or advanced breast cancer. Its objectives are to delineate the current state of knowledge regarding the efficacy of these treatments in the elderly population and their tolerance profile, including the impact on quality of life, with a particular focus on the frailest subgroups, and to attempt to define the optimal treatment strategy for elderly and fragile patients (dosage and therapeutic sequence). Background: Breast cancer (BC) incidence increases with age, particularly in HR-positive/HER2-negative subtypes. Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6is) alongside endocrine therapy (ET) have emerged as promising treatments for HR-positive/HER2-negative advanced and early BC. However, their efficacy, safety, and impact on quality of life (QoL) in older and frail patients remain underexplored. Methods: This position paper assesses the existing literature from 2015 to 2024, focusing on CDK4/6is use in patients aged 65 years and older with HR-positive/HER2-negative BC. Results: Our analysis methodically addresses critical questions regarding the utilization of CDK4/6is in the elderly BC patient population, organizing findings from the metastatic and adjuvant settings. In the metastatic setting, CDK4/6is significantly improve progression-free survival (PFS), paralleling benefits observed in younger patients, and suggest potential overall survival (OS) benefits, warranting further investigation. Despite an increased incidence of grade ≥ 3 adverse events (AEs), such as neutropenia and asthenia, CDK4/6is present a markedly lower toxicity profile compared to traditional chemotherapy, with manageable side effects. QoL analysis indicates that integrating CDK4/6is into treatment regimens does not significantly impact elderly BC patients' daily life and symptom management. Special attention is given to frail subgroups, and personalized approaches are recommended to balance efficacy and adverse effects, such as starting with ET alone and introducing CDK4/6is upon progression in patients with a low disease burden. Transitioning to the adjuvant setting, early results, particularly with abemaciclib, indicate positive effects on disease-free survival (DFS), emphasizing the need for continued analysis to validate these findings and assess long-term implications. However, data on older patients are insufficient to conclude whether they truly benefit from this treatment. Conclusion: Overall, CDK4/6is present a favorable benefit-risk profile in older BC patients, at least in advanced BC; however, further research is warranted to optimize treatment strategies and improve outcomes in this population [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach.
- Author
-
Dondi, Francesco, Antonelli, Alessandro, Suardi, Nazareno, Treglia, Giorgio, and Bertagna, Francesco
- Subjects
PROSTATE tumors treatment ,PUBLIC health surveillance ,MEDICAL information storage & retrieval systems ,PROSTATE-specific antigen ,AT-risk people ,PROSTATE tumors ,POSITRON emission tomography ,SYSTEMATIC reviews ,MEDLINE ,NUCLEAR medicine ,MEDICAL databases ,ONLINE information services ,TUMOR classification - Abstract
Simple Summary: The prognosis of prostate cancer (PCa) patients and their best therapeutic approach are related to the risk-based classification of this neoplasm since subjects with higher risk could have a higher incidence of recurrence. In addition, patients with low- and intermediate-risk PCa could benefit from active surveillance (AS). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has demonstrated its value for the assessment, prognostic role, and ability to guide the therapy of PCa. The aim of this systematic review was to assess the role of PSMA PET in guiding the correct classification of low-to-intermediate risk PCa subjects and the AS approach. Insights on the value of this imaging modality in these settings have emerged; however, further research in this field is necessary to clearly define the role of PSMA PET. Background: active surveillance (AS) is a suitable strategy for patients with prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is an established tool used to assess PCa. The aim of this review was to evaluate the role of PSMA imaging to guide correct risk-based classification and the AS approach in PCa patients. Methods: The Scopus, Embase, Web of Science, Cochrane Library, and PubMed/MEDLINE databases were screened to find relevant published articles. Results: 1774 articles were revealed with the literature search. A total of 1764 articles were excluded after applying exclusion criteria (data not within the field of interest, preclinical papers, conference proceedings, reviews, or editorials). Ten studies were finally included in the review, revealing that PSMA PET could have the ability to guide risk-based classification of PCa and the choice of AS, and to guide the execution of biopsies for the research of high-grade PCa, therefore precluding AS. Conclusion: this systematic review underlined a possible role of PSMA PET imaging in patients with PCa by correctly re-classifying them on the basis of their risk and guiding AS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023).
- Author
-
Fischerova, Daniela, Frühauf, Filip, Burgetova, Andrea, Haldorsen, Ingfrid S., Gatti, Elena, and Cibula, David
- Subjects
ENDOSCOPIC ultrasonography ,MAGNETIC resonance imaging ,METASTASIS ,LYMPH nodes ,CONTRAST media ,POSITRON emission tomography computed tomography ,MEDICAL protocols ,DIAGNOSTIC imaging ,TUMOR classification ,PELVIC tumors ,RADIOPHARMACEUTICALS ,CERVIX uteri tumors ,DECISION making in clinical medicine ,SENSITIVITY & specificity (Statistics) ,COMPUTED tomography ,DEOXY sugars ,MEDICAL societies ,DISEASE management - Abstract
Simple Summary: Constant technological development of modern imaging has led to substantial improvement in management and decision-making in the diagnostic and prognostic process of many different neoplasms. This also applies to cervical cancer. The main evidence, providing the base of recently updated ESGO-ESTRO-ESP recommendations (2023) on the management and treatment of cervical cancer, has been evaluated and reviewed in this paper. Ultrasound has been suggested as a valid alternative to MRI in primary diagnostic workup of cervical cancer if performed by an expert sonographer. Additionally, CT or PET/CT exhibits a substantial role in assessing the extrapelvic spread of the disease in locally advanced cases or when suspicious lymph nodes are detected. The purpose of this article is to provide a comprehensive review of the role of different imaging techniques in staging settings, displaying a focused interest in the use of ultrasound. Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques. After five years (2023), an update of the ESGO-ESTRO-ESP recommendations was performed, further confirming this statement. Transvaginal/transrectal ultrasound (TRS/TVS) or pelvic magnetic resonance (MRI) enables tumor delineation and precise assessment of its local extent, including the evaluation of the depth of infiltration in the bladder- or rectal wall. Additionally, both techniques have very high specificity to confirm the presence of metastatic pelvic lymph nodes but fail to exclude them due to insufficient sensitivity to detect small-volume metastases, as in any other currently available imaging modality. In early-stage disease (T1a to T2a1, except T1b3) with negative lymph nodes on TVS/TRS or MRI, surgicopathological staging should be performed. In all other situations, contrast-enhanced computed tomography (CECT) or 18F-fluorodeoxyglucose positron emission tomography combined with CT (PET-CT) is recommended to assess extrapelvic spread. This paper aims to review the evidence supporting the implementation of diagnostic imaging with a focus on ultrasound at primary diagnostic workup of cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Serum Interleukins 8, 17, and 33 as Potential Biomarkers of Colon Cancer.
- Author
-
Tâlvan, Constantin-Dan, Budișan, Liviuța, Tâlvan, Elena-Teodora, Grecu, Valentin, Zănoagă, Oana, Mihalache, Cosmin, Cristea, Victor, Berindan-Neagoe, Ioana, and Mohor, Călin Ilie
- Subjects
INTERLEUKINS ,COLON tumors ,DISEASE progression ,CYTOKINES ,METASTASIS ,EARLY detection of cancer ,TUMOR classification ,COMPARATIVE studies ,TUMOR markers - Abstract
Simple Summary: This research studied how three types of proteins, called interleukins (namely 8, 17A and 33), are present in the blood of healthy people and people with colon cancer. Colon cancer is a disease that affects the large intestine. The paper looked at 82 people, 42 of whom had colon cancer and 40 of whom did not. The researchers divided the cancer patients into four groups based on how severe their cancer was. The study measured the amount of interleukins in the blood of each person using a special test. The paper analyzed the results of the test, considering the age, gender, and cancer stage of each person. The results showed that younger people, and those with less severe cancer had more interleukins in their blood. The paper also found that two of the interleukins (8 and 17A) were higher in the cancer group, while one of them (33) was higher in the healthy group. The study also found that the interleukins were related to each other in both groups. This research concluded that the interleukins might help detect colon cancer and predict how it will progress. This paper could help improve the diagnosis and treatment of colon cancer. This research investigated the serum levels of three interleukins (IL8, IL17A, and IL33) and the possible relationships between them in healthy people and colon cancer patients at different stages. This study involved 82 participants, 42 of whom had colon cancer and 40 were healthy individuals. The cancer patients were classified into four groups according to the TNM staging classification of colon and rectal cancer. Serum levels of the interleukins were measured by the ELISA test. The data were analyzed statistically to compare the demographic characteristics, the interleukin levels across cancer stages, and the correlation between interleukins in both groups. The results showed that women had more early-stage colon cancer diagnoses, while men had more advanced-stage cancer diagnoses. Stage two colon cancer was more common in older people. Younger people, men, and those with early-stage colon cancer had higher levels of interleukins. The levels of IL8 and IL17A were higher in the cancer group, while the level of IL33 was higher in the healthy group. There was a strong correlation between IL8 and IL17A levels in both groups (p = 0.001). IL17A influenced the level of IL33 in the cancer group (p = 0.007). This study suggested that cytokine variation profiles could be useful for detecting colon cancer and predicting its outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Prognostic Significance of Preoperative Inflammation Markers on the Long-Term Outcomes in Peritoneal Carcinomatosis from Ovarian Cancer.
- Author
-
Balescu, Irina, Eftimie, Mihai, Petrea, Sorin, Diaconu, Camelia, Gaspar, Bogdan, Pop, Lucian, Varlas, Valentin, Hasegan, Adrian, Martac, Cristina, Bolca, Ciprian, Stoian, Marilena, Stroescu, Cezar, Zgura, Anca, and Bacalbasa, Nicolae
- Subjects
BIOMARKERS ,EVALUATION of medical care ,OVARIAN tumors ,PLATELET lymphocyte ratio ,PREOPERATIVE period ,INFLAMMATION ,PERITONEAL cancer ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,TUMOR classification ,NEUTROPHIL lymphocyte ratio ,SURVIVAL analysis (Biometry) ,RECEIVER operating characteristic curves ,MONOCYTE lymphocyte ratio - Abstract
Simple Summary: Ovarian cancer is still one of the deadliest malignancies affecting women worldwide which is associated with poor long-term outcomes even in certain cases in which complete debulking is achieved. In this respect, attention has been focused on identifying other prognostic factors which might indicate which cases are expected to have the best long-term outcomes such as the procoagulant or inflammatory status. The aim of the current paper is to analyse the correlation between the most frequently cited inflammatory and tumoral markers and the long-term outcomes of ovarian cancer patients. Ovarian cancer remains one of the most lethal gynaecological malignancies affecting women worldwide; therefore, attention has been focused on identifying new prognostic factors which might help the clinician to select cases who could benefit most from surgery versus cases in which neoadjuvant systemic therapy followed by interval debulking surgery should be performed. The aim of the current paper is to identify whether preoperative inflammation could serve as a prognostic factor for advanced-stage ovarian cancer. Material and methods: The data of 57 patients who underwent to surgery for advanced-stage ovarian cancer between 2014 and 2020 at the Cantacuzino Clinical Hospital were retrospectively reviewed. The receiver operating characteristic curve was used to determine the optimal cut-off value of different inflammatory markers for the overall survival analysis. The analysed parameters were the preoperative level of CA125, monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII). Results: Baseline CA125 > 780 µ/mL, NLR ≥ 2.7, MLR > 0.25, PLR > 200 and a systemic immune inflammation index (SII, defined as platelet × neutrophil–lymphocyte ratio) ≥ 84,1000 were associated with significantly worse disease-free and overall survival in a univariate analysis. In a multivariate analysis, MLR and SII were significantly associated with higher values of overall survival (p < 0.0001 and p = 0.0124); meanwhile, preoperative values of CA125, PLR and MLR were not associated with the overall survival values (p = 0.5612, p = 0.6137 and p = 0.1982, respectively). In conclusion, patients presenting higher levels of MLR and SII preoperatively are expected to have a poorer outcome even if complete debulking surgery is performed and should be instead considered candidates for neoadjuvant systemic therapy followed by interval surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. ENO2, a Glycolytic Enzyme, Contributes to Prostate Cancer Metastasis: A Systematic Review of Literature.
- Author
-
Zhou, Yuhan, Zeng, Feier, Richards, Gareth Owain, and Wang, Ning
- Subjects
ENZYME metabolism ,OSTEOBLAST metabolism ,RISK assessment ,CASTRATION-resistant prostate cancer ,GLYCOLYSIS ,PROSTATE tumors ,ENZYMES ,METASTASIS ,SYSTEMATIC reviews ,MEDLINE ,GENE expression ,CELL lines ,NEUROENDOCRINE tumors ,ONLINE information services ,TUMOR classification ,DISEASE risk factors - Abstract
Simple Summary: This paper reviews the role of ENO2, a protein involved in sugar metabolism, in advanced prostate cancer. Analysing five studies, we found that ENO2 levels tend to be higher in aggressive forms of prostate cancer, particularly those that have spread or become resistant to hormone therapy. This increased presence might be linked to how prostate cancer cells change their energy production as the disease progresses, shifting to rely more on sugar breakdown in advanced stages. The study also suggests that ENO2 can be influenced by the tumour's environment, such as low hormone levels or the presence of bone cells, which is relevant, as prostate cancer often spreads to bones. While not proving a direct causal relationship, the research indicates that ENO2 could be an important marker for aggressive disease and potentially a target for future treatments, warranting further investigation into its role in prostate cancer progression, especially in bone metastasis. Prostate cancer (PCa) is the second leading cause of male cancer deaths in the UK and the fifth worldwide. The presence of distant PCa metastasis can reduce the 5-year survival rate from 100% to approximately 30%. Enolase 2 (ENO2), a crucial glycolytic enzyme in cancer metabolism, is associated with the metastasis of multiple cancers and is also used as a marker for neuroendocrine tumours. However, its role in PCa metastasis remains unclear. In this study, we systematically reviewed the current literature to determine the association between ENO2 and metastatic PCa. Medline, Web of Science, and PubMed were searched for eligible studies. The search yielded five studies assessing ENO2 expression in PCa patients or cell lines. The three human studies suggested that ENO2 expression is correlated with late-stage, aggressive PCa, including castrate-resistant PCa (CRPC), metastatic CRPC, and neuroendocrine PCa (NEPC). This was further supported by two in vitro studies indicating that ENO2 expression can be regulated by the tumour microenvironment, such as androgen deprived conditions and the presence of bone-forming osteoblasts. Therefore, ENO2 may functionally contribute to PCa metastasis, possibly due to the unique metabolic features of PCa, which are glycolysis dependent only at the advanced metastatic stage. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radiomic Features and Resectability Criteria.
- Author
-
Miceli, Valentina, Gennarini, Marco, Tomao, Federica, Cupertino, Angelica, Lombardo, Dario, Palaia, Innocenza, Curti, Federica, Riccardi, Sandrine, Ninkova, Roberta, Maccioni, Francesca, Ricci, Paolo, Catalano, Carlo, Rizzo, Stefania Maria Rita, and Manganaro, Lucia
- Subjects
ONLINE information services ,OVARIAN tumors ,CONFIDENCE intervals ,PERITONEAL cancer ,MAGNETIC resonance imaging ,POSITRON emission tomography computed tomography ,TUMOR classification ,RADIOMICS ,DESCRIPTIVE statistics ,COMPUTED tomography ,MEDLINE ,DATA analysis software ,ODDS ratio ,SENSITIVITY & specificity (Statistics) ,DISEASE complications - Abstract
Simple Summary: Ovarian cancer is the second most frequent gynecological cancer in Western countries and the most common cause of death due to gynecological malignancies with an estimated five-year survival rate of 39%. The high aggressiveness and mortality are mainly related to the speed of abdominal spread: 70% of patients are diagnosed at an advanced stage of disease (stage III–IV FIGO) or in the presence of peritoneal carcinomatosis (PC), and about 60% of women will develop a recurrence. In this context, imaging plays an essential role for proper staging and follow-up and in selecting patients eligible for complete cytoreduction (CCR), the most important treatment and prognostic factor for patients. PC represents the most striking picture of the loco-regional spread of ovarian cancer, configuring stage III. In the last few years, many papers have evaluated the role of imaging and therapeutic management in patients with ovarian cancer and PC. This paper summed up the literature on traditional approaches to the imaging of peritoneal carcinomatosis in advanced ovarian cancer, presenting classification systems, most frequent patterns, routes of spread and sites that are difficult to identify. The role of imaging in diagnosis was investigated, with particular attention to the reported sensitivity and specificity data—computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography-CT (PET-CT)—and to the peritoneal cancer index (PCI). In addition, we explored the therapeutic possibilities and radiomics applications that can impact management of patients with ovarian cancer. Careful staging is mandatory, and patient selection is one of the most important factors influencing complete cytoreduction (CCR) outcome: an accurate pre-operative imaging may allow selection of patients that may benefit most from primary cytoreductive surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326.
- Author
-
Tâlvan, Constantin-Dan, Tâlvan, Elena-Teodora, Mohor, Călin Ilie, Budișan, Liviuța, Grecu, Valentin, Mihalache, Manuela, Zănoagă, Oana, Chira, Sergiu, Berindan-Neagoe, Ioana, Cristea, Victor, and Mohor, Cosmin Ioan
- Subjects
MICRORNA ,POLYMERASE chain reaction ,EARLY detection of cancer ,DISEASE management ,TUMOR markers ,SEVERITY of illness index ,COLON tumors ,GENE expression ,TUMOR classification ,DISEASE progression - Abstract
Simple Summary: This paper investigates the expression of miR-101-3p, miR-106a-5p, and miR-326 in colon cancer tissues compared to adjacent healthy tissues. This study involves 40 colon cancer patients, whose tissue samples were analyzed using qRT-PCR. Results indicate that these miRNAs are overexpressed in adjacent healthy tissues but decrease in advanced cancer stages. This study suggests a strong correlation between miR-106a-5p and miR-326 with colon cancer severity. The findings propose that miRNA profiling could be useful for early diagnosis and prognosis in colon cancer management. Early diagnosis and prognosis of cancer progression through biomarker profiling are crucial in managing colon cancer patients. Our research aimed to investigate the expression of miR-101-3p, miR-106a-5p, and miR-326 in tumor and adjacent healthy tissues of colon cancer patients and determine their potential diagnostic utility. This study included 40 patients divided into four groups according to the TNM staging classification. MiRNA expression was analyzed using qRT-PCR. The results showed that miR-101-3p, miR-106a-5p, and miR-326 are overexpressed in adjacent healthy tissues but decrease in advanced cancer stages. MiR-106a-5p and miR-326 are strongly correlated with colon cancer severity. These findings suggest that miRNA profiling could be useful for early diagnosis and prognosis in colon cancer management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Role of 18 F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications.
- Author
-
Caldarella, Carmelo, De Risi, Marina, Massaccesi, Mariangela, Miccichè, Francesco, Bussu, Francesco, Galli, Jacopo, Rufini, Vittoria, and Leccisotti, Lucia
- Subjects
HEAD & neck cancer diagnosis ,HEAD & neck cancer treatment ,SQUAMOUS cell carcinoma ,RADIOPHARMACEUTICALS ,MEDICAL technology ,RADIOTHERAPY ,COMPUTED tomography ,DEOXY sugars ,RADIOMICS ,POSITRON emission tomography ,TREATMENT effectiveness ,MAGNETIC resonance imaging ,COMPUTERS in medicine ,TUMOR classification ,MACHINE learning ,NECK surgery - Abstract
Simple Summary: Among head–neck tumors, squamous cell carcinoma is the most frequent histotype and includes a range of malignancies with different sites of origin as well as different therapeutic strategies and clinical outcomes. In daily practice, patients with head–neck squamous cell carcinoma are seen in various clinical settings, requiring a multidisciplinary approach to therapeutic decisions and clinical care.
18 F-FDG PET/CT plays a well-defined role in the management of these tumors for pre-treatment staging and radiotherapy planning as well as treatment-response assessment and post-therapy follow-up. This paper is an overview of the standard use of18 F-FDG PET/CT in the various clinical scenarios of head–neck squamous cell carcinoma. Also, emerging applications will be reviewed, including the use of radiopharmaceuticals other than18 F-FDG, PET/MRI implementation in clinical practice, and the use of radiomics and machine learning. This article provides an overview of the use of18 F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head–neck imaging interpretation are described. In the initial work-up,18 F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various18 F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning,18 F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value,18 F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than18 F-FDG, which can answer specific clinical needs. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning.
- Author
-
Abidalkareem, Ali, Ibrahim, Ali K., Abd, Moaed, Rehman, Oneeb, and Zhuang, Hanqi
- Subjects
BREAST tumor diagnosis ,BREAST tumor treatment ,BREAST tumors ,MICRORNA ,EARLY detection of cancer ,CANCER patients ,TUMOR markers ,GENE expression ,RNA probes ,CLINICAL pathology ,METASTASIS ,ONCOGENES ,TUMOR classification ,MACHINE learning ,COMPARATIVE studies ,MOLECULAR diagnosis ,MOLECULAR pathology ,SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: Metastatic breast cancer is an aggressive disease that early diagnostic attempts is of an utmost importance. A machine learning model that utilizes NCA and MRMR in this work is attempting to isolate pertinent dysregulated miRNA's for the different four cancer stages. This work compares the current clinical diagnostic approaches with the proposed ML model results. Determining the tumor origin in humans is vital in clinical applications of molecular diagnostics. Metastatic cancer is usually a very aggressive disease with limited diagnostic procedures, despite the fact that many protocols have been evaluated for their effectiveness in prognostication. Research has shown that dysregulation in miRNAs (a class of non-coding, regulatory RNAs) is remarkably involved in oncogenic conditions. This research paper aims to develop a machine learning model that processes an array of miRNAs in 1097 metastatic tissue samples from patients who suffered from various stages of breast cancer. The suggested machine learning model is fed with miRNA quantitative read count data taken from The Cancer Genome Atlas Data Repository. Two main feature-selection techniques have been used, mainly Neighborhood Component Analysis and Minimum Redundancy Maximum Relevance, to identify the most discriminant and relevant miRNAs for their up-regulated and down-regulated states. These miRNAs are then validated as biological identifiers for each of the four cancer stages in breast tumors. Both machine learning algorithms yield performance scores that are significantly higher than the traditional fold-change approach, particularly in earlier stages of cancer, with Neighborhood Component Analysis and Minimum Redundancy Maximum Relevance achieving accuracy scores of up to 0.983 and 0.931, respectively, compared to 0.920 for the FC method. This study underscores the potential of advanced feature-selection methods in enhancing the accuracy of cancer stage identification, paving the way for improved diagnostic and therapeutic strategies in oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. A Biopsy-Controlled Prospective Study of Contrast-Enhancing Diffuse Glioma Infiltration Based on FET-PET and FLAIR.
- Author
-
Harat, Maciej, Miechowicz, Izabela, Rakowska, Józefina, Zarębska, Izabela, and Małkowski, Bogdan
- Subjects
BRAIN anatomy ,BIOPSY ,GLIOMAS ,DIAGNOSTIC imaging ,COMPUTED tomography ,POSITRON emission tomography ,DESCRIPTIVE statistics ,LONGITUDINAL method ,TYROSINE ,TUMOR classification ,CONTRAST media ,SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: Currently, contrast-enhancing gliomas FLAIRectomies or supramarginal gliresections are gaining momentum. This paper presents a semiquantitative analysis of FET uptake in biopsy targets inside and outside glioma masses based on PET/MR images. An exact threshold to differentiate glioma and astrogliosis within FLAIR using dual-timepoint PET acquisition and referring to various anatomical structures is a major strength of this study. Doing so paves the way for an optimized PET protocol to enable precise and reproducible FET-PET quantification for glioma mapping in clinical trials and practice. Accurately defining glioma infiltration is crucial for optimizing radiotherapy and surgery, but glioma infiltration is heterogeneous and MRI imperfectly defines the tumor extent. Currently, it is impossible to determine the tumor infiltration gradient within a FLAIR signal. O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET often reveals high-grade glioma infiltration beyond contrast-enhancing areas on MRI. Here, we studied FET uptake dynamics in tumor and normal brain structures by dual-timepoint (10 min and 40–60 min post-injection) acquisition to optimize analysis protocols for defining glioma infiltration. Over 300 serial stereotactic biopsies from 23 patients (mean age 47, 12 female/11 male) of diffuse contrast-enhancing gliomas were taken from areas inside and outside contrast enhancement or outside the FET hotspot but inside FLAIR. The final diagnosis was G4 in 11, grade 3 in 10, and grade 2 in 2 patients. The target-to-background (TBRs) ratios and standardized uptake values (SUVs) were calculated in areas used for biopsy planning and in background structures. The optimal method and threshold values were determined to find a preferred strategy for defining glioma infiltration. Standard thresholding (1.6× uptake in the contralateral brain) in standard acquisition PET images differentiated a tumor of any grade from astrogliosis, although the uptake in astrogliosis and grade 2 glioma was similar. Analyzing an optimal strategy for infiltration volume definition astrogliosis could be accurately differentiated from tumor samples using a choroid plexus as a background. Early acquisition improved the AUC in many cases, especially within FLAIR, from 56% to 90% sensitivity and 41% to 61% specificity (standard TBR 1.6 vs. early TBR plexus). The current FET-PET evaluation protocols for contrast-enhancing gliomas are limited, especially at the tumor border where grade 2 tumor and astrogliosis have similar uptake, but using choroid plexus uptake in early acquisitions as a background, we can precisely define a tumor within FLAIR that was outside of the scope of current FET-PET protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes.
- Author
-
Di Martino, Marcello, Vitale, Alessandro, Ferraro, Daniele, Maniscalco, Marilisa, Pisaniello, Donatella, Arenga, Giuseppe, Falaschi, Federica, Terrone, Alfonso, Iacomino, Alessandro, Galeota Lanza, Alfonso, Esposito, Ciro, Cillo, Umberto, and Vennarecci, Giovanni
- Subjects
META-analysis ,CONFIDENCE intervals ,SYSTEMATIC reviews ,TREATMENT effectiveness ,TUMOR classification ,CANCER patients ,DESCRIPTIVE statistics ,LIVER transplantation ,INTENTION ,MEDLINE ,ODDS ratio ,HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Downstaging therapies provides a viable alternative approach for expanding the MC limits and selecting a subgroup of patients whose LT candidacy would otherwise be disregarded. However, data on downstaging are still controversial due to a variety of reasons, such as differences in LRT, the wide variability in waiting time before LT and, particularly, the lack of intention-to-treat (ITT) analyses. This article is a systematic review and intends to synthesise the existing evidence about the effectiveness of downstaging therapies, aiming to: (a) assess outcomes from ITT analysis of patients with liver cirrhosis and HCC beyond the listing criteria and selected for downstaging protocol, in comparison with HCC within the listing criteria; (b) evaluate outcomes of patients with liver cirrhosis HCC beyond the listing criteria successfully downstaged and transplanted versus those not transplanted. Background: Locoregional therapies (LRTs) are commonly used to increase the number of potential candidates for liver transplantation (LT). The aim of this paper is to assess the outcomes of LRTs prior to LT in patients with hepatocellular carcinoma (HCC) beyond the listing criteria. Methods: In accordance with the PRISMA guidelines, we searched the Medline and Web of Science databases for reports published before May 2021. We included papers assessing adult patients with HCC considered for LT and reporting intention-to-treat (ITT) survival outcomes. Two reviewers independently identified and extracted the data and evaluated the papers. Outcomes analysed were drop-out rate; time on the waiting list; and 1, 3 and 5 year survival after LT and based on an ITT analysis. Results: The literature search yielded 3,106 records, of which 11 papers (1874 patients) met the inclusion criteria. Patients with HCC beyond the listing criteria and successfully downstaged presented a higher drop-out rate (OR 2.05, 95% CI 1.45–2.88, p < 0.001) and a longer time from the initial assessment to LT than those with HCC within the listing criteria (MD 1.93, 95% CI 0.91–2.94, p < 0.001). The 1, 3 and 5 year survival post-LT and based on an ITT analysis did not show significant differences between the two groups. Patients with HCC beyond the listing criteria, successfully downstaged and then transplanted, presented longer 3 year (OR 3.77, 95% CI 1.26–11.32, p = 0.02) and 5 year overall survival (OS) (OR 3.08, 95% CI 1.15–8.23, p = 0.02) in comparison with those that were not submitted to LT. Conclusions: Patients with HCC beyond the listing criteria undergoing downstaging presented a higher drop-out rate in comparison with those with HCC within the listing criteria. However, the two groups did not present significant differences in 1, 3 and 5 year survival rates based on an ITT analysis. Patients with HCC beyond the listing, when successfully downstaged and transplanted, presented longer 3 and 5-year OS in comparison with those who were not transplanted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management.
- Author
-
Orme, Sophie E. and Moncrieff, Marc D.
- Subjects
MELANOMA prognosis ,MEDICAL protocols ,SENTINEL lymph node biopsy ,MELANOMA ,SKIN tumors ,CANCER relapse ,TUMOR classification ,SECONDARY primary cancer ,SYMPTOMS - Abstract
Simple Summary: The vast majority of patients who present with a primary cutaneous melanoma can be cured by surgery alone. Although a wider local excision margin around the primary tumour may in theory maximize the chance of cure, the result is a larger wound that often requires a more complex operation to close, as well as greater risk of surgical complications, morbidity, and higher associated healthcare costs. Despite several previous studies, we have yet to reach agreement internationally over what excision margin is optimal. This paper reviews the evidence for current guidelines for wide local excision margins; explores the challenges of extrapolating the findings of previous randomised trials into clinical practice within the rapidly evolving landscape of modern melanoma management; and finally discusses the potential of the actively enrolling MelMarT-II trial to provide a definitive answer to the question: how wide is wide enough? Surgical wide local excision (WLE) remains the current standard of care for primary cutaneous melanoma. WLE is an elective procedure that aims to achieve locoregional disease control with minimal functional and cosmetic impairment. Despite several prospective randomised trials, the optimal extent of excision margin remains controversial, and this is reflected in the persistent lack of consensus in guidelines globally. Furthermore, there is now the added difficulty of interpreting existing trial data in the context of the evolving role of surgery in the management of melanoma, with our increased understanding of clinicopathologic and genomic prognostic markers leading to the often routine use of sentinel node biopsy (SNB) as a staging procedure, in addition to the development of adjuvant systemic therapies for high-risk disease. An ongoing trial, MelMarT-II, has been designed with the aim of achieving a definitive answer to guide this fundamental surgical decision. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Saving Lives in Thoracic Surgery: Balancing Oncological Radicality and Functional Preservation, Transitioning from Standard Pneumonectomy to Targeted Sublobar Resection.
- Author
-
Eguchi, Takashi, Kumeda, Hirotaka, Miura, Kentaro, Hamanaka, Kazutoshi, and Shimizu, Kimihiro
- Subjects
LUNG physiology ,THORACIC surgery ,MINIMALLY invasive procedures ,SURGICAL robots ,FUNCTIONAL status ,LUNG tumors ,TUMOR classification ,PNEUMONECTOMY ,CANCER patient medical care - Abstract
Simple Summary: This manuscript provides a detailed analysis of the advancements in thoracic surgery. It traces the journey from the standard pneumonectomy to the precise approach of sublobar resections. The manuscript emphasizes the emergence and acceptance of advanced techniques such as robotic-assisted surgery. It also highlights the pivotal role of preserving organ functionality while ensuring oncological radicality, which is especially important when treating early-stage lung cancer. Through a comprehensive review of contemporary surgical methods and their clinical outcomes, this paper explains the delicate balance that modern thoracic surgeons must achieve between aggressive cancer removal and preserving the quality of life. It thereby contributes to the ongoing refinement of the field. This review chronicles the evolution of thoracic surgical interventions, from the standardized pneumonectomy to the precise approach of sublobar resections. It discusses the emergence and acceptance of minimally invasive and robot-assisted surgical techniques, highlighting their impact on improving outcomes beyond cancer and their influence on the surgical management of early-stage lung cancer. Evaluating historical developments alongside present methodologies, this review underscores the critical need for meticulous surgical planning and execution to optimize both oncological radicality and functional preservation. This evolution portrayed not only technical advancements but also a shift in the clinical approach towards tailored, organ-preserving methodologies, culminating in a contemporary framework promoting sublobar resections as the standard for specific patient profiles, signifying a new era of precision in thoracic surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Impact of Nutritional Status of Patients with Head and Neck Squamous Cell Carcinoma on the Expression Profile of Ghrelin, Irisin, and Titin.
- Author
-
Andruszko, Agata, Szydłowski, Jarosław, Grabarek, Beniamin Oskar, Mazur, Katarzyna, Sirek, Tomasz, Ossowski, Piotr, Kozikowski, Mieszko, Kaminiów, Konrad, Zybek-Kocik, Ariadna, and Banaszewski, Jacek
- Subjects
HEAD & neck cancer diagnosis ,MUSCLE protein metabolism ,MUSCLE proteins ,MYOKINES ,HEAD & neck cancer ,BLOOD collection ,GHRELIN ,TUMOR classification ,MOLECULAR biology ,DNA methylation ,METHYLATION ,MESSENGER RNA ,ENZYME-linked immunosorbent assay ,TISSUES ,HISTOLOGY ,POLYMERASE chain reaction ,BODY mass index ,SQUAMOUS cell carcinoma ,NUTRITIONAL status ,BLOOD - Abstract
Simple Summary: Cachexia and malnutrition are characteristic of oncology patients, including those with head and neck cancer (HNSCC). Fifty-six patients diagnosed with HNSCC (study group) were included in the study, and seventy patients constituted the control group. We used standardized questionnaires to assess nutritional status and cachexia. In our study, we evaluated whether ghrelin, titin, and irisin can be a useful diagnostic marker, a prognostic marker of cancer development in these patients, and whether the levels of these proteins depend on the nutritional status of the patients. We used molecular biology methods to evaluate the concentration of the selected proteins. The results indicate that the levels of ghrelin, titin, and irisin correlate well with the nutritional and cachexia status of patients with HNSCC. Until now, to our best knowledge, this is the first study assessing the changes in concentrations of these proteins in this type of cancer. The goal of this paper was the evaluation of the changes in the expression profile of irisin, ghrelin, and titin in the carcinoma tissue and in the blood of patients with head and neck squamous cell carcinoma (HNSCC), including determining the profile of their expression in relation to patient nutrition. The study included 56 patients with diagnosed squamous cell carcinoma of HNSCC in the T3 and T4 stages of the disease. Healthy control tissue specimens were collected from an area 10 mm outside the histologically negative margin. In turn, the blood and serum from the control group came from healthy volunteers treated for non-oncologic reasons (n = 70). The molecular analysis allowed us to determine the profile of irisin, ghrelin, and titin methylation, evaluate their expression on the level of mRNA (quantitative Reverse Transcription Polymerase Chain Reaction; qRT-PCR) and protein (Enzyme-Linked Immunosorbent Assay Reaction; ELISA) in the carcinoma tissue and the margin of healthy tissue, as well as in serum of patients in the study and control groups. At the start of our observations, a Body Mass Index (BMI) < 18.5 was noted in 42 of the patients, while six months after the treatment a BMI < 18.5 was noted in 29 patients. We also noted a decrease in the expression of irisin, ghrelin, and titin both on the level of mRNA and protein, as well as a potential regulation of their expression via DNA methylation. There is no convincing evidence that the proteins assayed in the present work are specific with regard to HNSSC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage.
- Author
-
Ionescu, Filip, Nguyen, Jonathan, Segura, Carlos Moran, Paravathaneni, Mahati, Grass, G. Daniel, Johnstone, Peter, Zacharias, Niki M., Pettaway, Curtis A., Lu, Xin, Kim, Youngchul, Whiting, Junmin, Dhillon, Jasreman, Eschrich, Steven A., Chadha, Juskaran, Gullapalli, Keerthi, Roman Souza, Gabriel, Miyagi, Hiroko, Manley, Brandon J., Spiess, Philippe E., and Chahoud, Jad
- Subjects
IMMUNOLOGICAL tolerance ,DISEASE progression ,BIOCHEMISTRY ,PENILE tumors ,IMMUNE checkpoint inhibitors ,PHENOMENOLOGICAL biology ,CYTOMETRY ,MACROPHAGES ,CELL physiology ,TUMOR classification ,CANCER patients ,FLUORESCENT antibody technique ,PAPILLOMAVIRUS diseases ,DESCRIPTIVE statistics ,SQUAMOUS cell carcinoma - Abstract
Simple Summary: Penile cancer is a rare and aggressive disease. Current treatment options when the cancer is locally advanced are suboptimal and potentially mutilating. Insight into the immune dysregulation necessary for the emergence of penile cancer could suggest innovative ways to manipulate the immune system which have already demonstrated efficacy in other, more common malignancies. In this paper, we use multiplex immunofluorescence, a novel technology, to investigate the immune microenvironment of penile cancer for the first time. We describe a pattern of immune exhaustion as cancer becomes more advanced and identify tumor-associated macrophages as a potential key player in regulating this process. Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a subset of patients suggests immune escape may play an important role in tumorigenesis. Herein, we explored for the first time the immune microenvironment of 57 men with PSCC and how it varies with the presence of human papillomavirus (HPV) infection and across tumor stages using multiplex immunofluorescence of key immune cell markers. We observed an increase in the density of immune effector cells in node-negative tumors and a progressive rise in inhibitory immune players such as type 2 macrophages and upregulation of the PD-L1 checkpoint in men with N1 and N2-3 disease. There were no differences in immune cell densities with HPV status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. PET/CT in Prostate Cancer.
- Author
-
Evangelista, Laura and Fanti, Stefano
- Subjects
PROSTATE tumors treatment ,COMPUTERS in medicine ,SERIAL publications ,POSITRON emission tomography computed tomography ,ARTIFICIAL intelligence ,DIAGNOSTIC imaging ,TREATMENT effectiveness ,TUMOR classification ,RADIOPHARMACEUTICALS ,PROSTATE tumors ,EVALUATION - Published
- 2023
- Full Text
- View/download PDF
20. Higher Content but No Specific Activity in Gelatinase B (MMP-9) Compared with Gelatinase A (MMP-2) in Human Renal Carcinoma.
- Author
-
Młynarczyk, Grzegorz, Gudowska-Sawczuk, Monika, Mroczko, Barbara, Bruczko-Goralewska, Marta, Romanowicz, Lech, and Tokarzewicz, Anna
- Subjects
COLLAGEN ,WESTERN immunoblotting ,CARCINOGENESIS ,PROTEOLYTIC enzymes ,TUMOR classification ,KIDNEY tumors ,RESEARCH funding ,ENZYME-linked immunosorbent assay ,FLUORIMETRY ,ENZYMES ,EXTRACELLULAR space - Abstract
Simple Summary: Gelatinases are one of the major groups of matrix metalloproteinases. Gelatinase A which known as matrix metalloproteinase-2 and gelatinase B referred to as matrix metalloproteinase -9 play a crucial role in breaking down gelatin and various components of the extracellular matrix, including denatured collagen. It has been observed that, in cancer gelatinases are often associated with an-giogenesis, tumor invasion and metastasis.Matrix metalloproteinases have been studied for their involvement in the progression of various tumors in recent years. This paper analyses the contribu-tion of gelatinases A and B in human renal carcinoma pathogenesis, showing their opposite action both at the stage of extracellular matrix remodeling and at different stages of renal tumor devel-opment. Based on the obtained results, MMP-9 showed higher content and lower specific activity compared with MMP-2. Gelatinases belong to a group of enzymes known as matrix metalloproteinases (MMPs). Gelatinases A and B (MMP-2 and MMP-9, respectively) are the enzymes with the highest ability to destroy collagen, primarily type IV collagen, which is an essential component of the base membrane. Hence, it can be assumed that they are involved, among other things, with the metastasis process of cancer. As a result, the objective of this study was to assess the presence, activity, and expression of selected gelatinases in human renal cancer. Healthy (n = 20) and clear-cell kidney cancer tissue samples (G2 n = 10, G3 n = 10) were analyzed. The presence and content of MMPs were measured using the Western blot and ELISA methods, respectively. The activity (actual and specific) was analyzed with a fluorimetric method. The presence of both investigated enzymes was demonstrated in the representative zymogram. MMP-9 showed the most intensive saturation. It has been observed that both gelatinases occur primarily in high molecular complexes in the human kidney, regardless of whether it is a control or tumor tissue. Both gelatinases were present in comparable amounts in healthy tissues of the kidney. MMP-9 showed a higher content than MMP-2 in both renal cancer grades, but we observed the enhanced activity of both gelatinases with an increase in the grade of renal cancer. A higher MMP-9 content and, on the other hand, lower specific activity in the cancer tissue suggest that MMP-9 is predominantly present in an inactive form in renal cancer. The higher activity of MMP-9 demonstrated using the zymography method may be a cause of different values of activity that depend on the phase of the carcinogenic process. The present study revealed changes in the tested gelatinases in healthy and cancerous tissues of renal cell carcinoma. Therefore, it can be concluded that matrix metalloproteinases 2 and 9 are enzymes directly involved in carcinogenesis, and hence, it seems that MMPs may have potential in the diagnosis and treatment of renal carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Multiparametric Magnetic Resonance Imaging of Penile Cancer: A Pictorial Review.
- Author
-
Switlyk, Marta D., Hopland, Andreas, Reitan, Edmund, Sivanesan, Shivanthe, Brennhovd, Bjørn, Axcrona, Ulrika, and Hole, Knut H.
- Subjects
PHYSICAL diagnosis ,PENILE tumors ,MAGNETIC resonance imaging ,CONTRAST media ,TUMOR classification ,MEDICAL protocols ,DECISION making in clinical medicine - Abstract
Simple Summary: Accurate preoperative staging and precise outlining of a tumor's extent are crucial for selecting the most suitable treatment approach and improving outcomes. The current clinical staging of penile cancer is still largely based on physical examination. Multiparametric magnetic resonance imaging (mpMRI) is an important imaging modality that complements physical examination and reduces uncertainties that can easily arise during this examination. However, evidence for the application of MRI in the assessment of penile cancer is scarce; there is no consensus on MRI protocols, and functional MRI techniques have not been widely studied before. This paper focuses on the diagnostic performance of non-erectile mpMRI in evaluating penile cancer, reviewing the use of functional techniques for comprehensive oncological assessments together with the current literature and the latest guidelines. The role of multiparametric magnetic resonance imaging (mpMRI) in assessing penile cancer is not well defined. However, this modality may be successfully applied for preoperative staging and patient selection; postoperative local and regional surveillance; and assessments of treatment response after oncological therapies. Previous studies have been mostly limited to a few small series evaluating the accuracy of MRI for the preoperative staging of penile cancer. This review discusses the principles of non-erectile mpMRI, including functional techniques and their applications in evaluating the male genital region, along with clinical protocols and technical considerations. The latest clinical classifications and guidelines are reviewed, focusing on imaging recommendations and discussing potential gaps and disadvantages. The development of functional MRI techniques and the extraction of quantitative parameters from these sequences enables the noninvasive assessment of phenotypic and genotypic tumor characteristics. The applications of advanced techniques in penile MRI are yet to be defined. There is a need for prospective trials and feasible multicenter trials due to the rarity of the disease, highlighting the importance of minimum technical requirements for MRI protocols, particularly image resolution, and finally determining the role of mpMRI in the assessment of penile cancer [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing.
- Author
-
Welham, Zoe, Li, Jun, Engel, Alexander F., and Molloy, Mark P.
- Subjects
RNA analysis ,STOMACH tumors ,COLON polyps ,SEQUENCE analysis ,INFLAMMATORY bowel diseases ,GUT microbiome ,TUMOR classification ,COMPARATIVE studies ,GENES ,RESEARCH funding ,TECHNOLOGY - Abstract
Simple Summary: Changes in the gut microbiome are associated with bowel cancers, however, less is known about the microbiome during the pre-cancerous bowel polyp stage. This study compared two DNA sequencing technologies to identify the gut microbiome from mucosa of colonoscopy patients diagnosed with bowel polyps or without bowel polyps. We found that different sequencing technologies and bioinformatic pipelines impact on bacterial taxonomy assignments. Overall, there were only minor differences in gut microbiome communities between participants with bowel polyps and those without. However, Ruminococcus gnavus, a bacteria commonly associated with inflammatory bowel disease (IBD) was shown to be more abundant in participants with polyps, despite participants with IBD being exclude from this study. This paper adds to our knowledge of the gut microbiome associated with bowel neoplasia. Numerous studies have correlated dysbiosis in stool microbiota with colorectal cancer (CRC); however, fewer studies have investigated the mucosal microbiome in pre-cancerous bowel polyps. The short-read sequencing of variable regions in the 16S rRNA gene has commonly been used to infer bacterial taxonomy, and this has led, in part, to inconsistent findings between studies. Here, we examined mucosal microbiota from patients who presented with one or more polyps, compared to patients with no polyps, at the time of colonoscopy. We evaluated the results obtained using both short-read and PacBio long-read 16S rRNA sequencing. Neither sequencing technology identified significant differences in microbial diversity measures between patients with or without bowel polyps. Differential abundance measures showed that amplicon sequence variants (ASVs) associated with Ruminococcus gnavus and Escherichia coli were elevated in mucosa from polyp patients, while ASVs associated with Parabacteroides merdae, Veillonella nakazawae, and Sutterella wadsworthensis were relatively decreased. Only R. gnavus was consistently identified using both sequencing technologies as being altered between patients with polyps compared to patients without polyps, suggesting differences in technologies and bioinformatics processing impact study findings. Several of the differentially abundant bacteria identified using either sequencing technology are associated with inflammatory bowel diseases despite these patients being excluded from the current study, which suggests that early bowel neoplasia may be associated with a local inflammatory niche. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.
- Author
-
González-Moles, Miguel Ángel, Warnakulasuriya, Saman, López-Ansio, María, and Ramos-García, Pablo
- Subjects
TUMOR classification ,MOUTH tumors ,SYSTEMATIC reviews ,OROPHARYNGEAL cancer ,ORAL diseases ,EVIDENCE gaps ,CELLS ,LITERATURE reviews ,TUMORS - Abstract
Simple Summary: This scoping review of systematic reviews aims to accurately assess the degree of existing scientific evidence on the cancer hallmarks proposed in 2011 by Hanahan and Weinberg, in the form of systematic reviews and meta-analyses, applied to oral potentially malignant disorders, oral cavity and oropharyngeal squamous cell carcinomas, in order to point out gaps in evidence and lines of research that should be implemented in the future to improve the malignant transformation prediction, diagnosis and/or prognosis of these diseases. In 2000 and 2011, Hanahan and Weinberg published two papers in which they defined the characteristics that cells must fulfil in order to be considered neoplastic cells in all types of tumours that affect humans, which the authors called "hallmarks of cancer". These papers have represented a milestone in our understanding of the biology of many types of cancers and have made it possible to reach high levels of scientific evidence in relation to the prognostic impact that these hallmarks have on different tumour types. However, to date, there is no study that globally analyses evidence-based knowledge on the importance of these hallmarks in oral and oropharyngeal squamous cell carcinomas. For this reason, we set out to conduct this scoping review of systematic reviews with the aim of detecting evidence gaps in relation to the relevance of the cancer hallmarks proposed by Hanahan and Weinberg in oral and oropharyngeal cancer, and oral potentially malignant disorders, and to point out future lines of research in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Oral Cavity Cancer Tissues Differ in Isotopic Composition Depending on Location and Staging.
- Author
-
Bogusiak, Katarzyna, Kozakiewicz, Marcin, Puch, Aleksandra, Mostowski, Radosław, Paneth, Piotr, and Kobos, Józef
- Subjects
NITROGEN analysis ,ISOTOPIC analysis ,HEAD & neck cancer ,LIP tumors ,TUMOR classification ,DESCRIPTIVE statistics ,RESEARCH funding ,COLLECTION & preservation of biological specimens ,ORAL mucosa ,HISTOLOGY ,SQUAMOUS cell carcinoma ,ISOTOPES ,MOUTH ,LIPS - Abstract
Simple Summary: Oral squamous cell carcinomas (OSCCs) pose significant therapeutic challenges. Despite the advancement of treatment methods, they are still characterised by a poor prognosis. The isotopic abundance of oral cancers reflects their biology. A better understanding of OSCC biology may improve treatment outcomes. In this study, the isotopic compositions of the nitrogen and carbon of OSCC tissue samples were investigated across different oral cancer localisations. The correlations between the isotopic composition and clinical and histological advancement were established. The results suggest that assessment of the isotopic composition might serve as a valuable tool for determining tumour biology and behaviour. The aim of this paper was to characterise the isotopic composition of oral squamous cell carcinoma (OSCC) specimens of different areas of the oral cavity. Secondly, we assessed whether there was a correlation between clinical stages of OSCC and isotopic abundance. The IRMS procedure was performed on 124 samples derived from 31 patients with OSCC of 15 N and 13 C to assess the isotopic composition. From each individual, four samples from the tumour, two from the margins, and two samples of healthy oral mucous membranes were derived. The two samples from the tumour and two samples from the margin were additionally subjected to histopathological assessment. Then, statistical analysis was conducted. Tumour infiltration tissues of the lower lip were characterised by higher mean δ
13 C values compared to samples derived from cancers of the other oral cavity regions (−23.82 ± 1.21 vs. −22.67 ± 1.35); (p = 0.04). The mean percentage of nitrogen content in tumour tissues was statistically higher in patients with the most advanced cancers (11.89 ± 0.03%) versus the group of patients with II and III stage cancers (11.12 ± 0.02%); (p = 0.04). In patients at stage IV, the mean δ13 C value in the cancer samples equalled −22.69 ± 1.42 and was lower than that in patients at less severe clinical stages (p = 0.04). Lower lip cancer tissues differed in the isotopic abundance of carbon in comparison with tissues derived from the group of combined samples from other locations. Values of δ13 C observed in specimens derived from lower lip cancers were similar to those observed in healthy oral mucous membranes. Cancer tissues obtained from patients in the last stage of OSCC had a different isotopic composition in comparison with those obtained from earlier stages. To confirm these observations, further research on larger groups of patients is needed. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
25. The Relation of Lifestyle with Inflammation at the Time of Diagnosis in Patients with Colorectal Cancer.
- Author
-
Gielen, Anke H. C., Melenhorst, Jarno, Breukink, Stephanie O., Weijenberg, Matty P., and Bours, Martijn J. L.
- Subjects
LIFESTYLES ,BIOMARKERS ,INTERLEUKINS ,CONFIDENCE intervals ,INFLAMMATION ,CROSS-sectional method ,COLORECTAL cancer ,TREATMENT effectiveness ,TUMOR classification ,ALCOHOL drinking ,RESEARCH funding ,TUMOR necrosis factors ,MALNUTRITION ,BODY mass index ,SMOKING ,NUTRITIONAL status ,DISEASE risk factors - Abstract
Simple Summary: Large intestinal cancer is one of the most common lifestyle-related types of cancer. However, the exact mechanism in the relation between adipose tissue, systemic inflammation and intestinal cancer remains unknown. Furthermore, there are many hypotheses regarding the pathways in which alcohol consumption, smoking, malnutrition and physical inactivity cause low-grade systemic inflammation. In this paper, we discuss the relation of lifestyle with inflammation, in terms of inflammatory markers at the time of diagnosis in intestinal cancer patients. Our findings suggest that an overall unhealthier lifestyle and a higher risk of malnutrition at the time of diagnosis were associated with elevated levels of inflammatory markers. These findings could contribute to formulating lifestyle advice in the future. Colorectal cancer is one of the most common lifestyle-related types of cancer. The exact pathophysiologic mechanism in the relation between (visceral) adipose tissue, systemic inflammation and colorectal cancer remains unknown. This study aimed to assess the association of lifestyle with markers of systemic inflammation at the time of diagnosis in stage I-III colorectal cancer patients. Patients (n = 298) with stage I-III colorectal cancer from three Dutch hospitals were included at diagnosis. Several lifestyle-related variables (MUST nutritional status score, WCRF/AICR healthy lifestyle score, active smoking, alcohol consumption and BMI) and inflammatory markers (plasma levels of IL-6, IL-8, IL-10, TNFα and 'high sensitive' hsCRP) were measured at the time of diagnosis. Confounder-adjusted multivariable linear regression models were used to analyse how the lifestyle variables were associated with the inflammatory markers. Statistically significant associations were found between a better WCRF/AICR lifestyle score and lower levels of IL-6 and hsCRP. A medium and high risk of malnutrition according to the MUST score was associated with elevated levels of both IL-8 and hsCRP. An overall unhealthier lifestyle indicated by a lower WCRF/AICR lifestyle score and a higher risk of malnutrition according to the MUST score at the time of diagnosis was associated with elevated levels of inflammatory markers. These findings can contribute to formulating lifestyle advice to improve treatment outcomes and prognosis in patients having CRC in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives.
- Author
-
Iezzi, Roberto, Posa, Alessandro, Contegiacomo, Andrea, Lee, In Joon, Bale, Reto, Tanzilli, Alessandro, Tenore, Lorenzo, Giuliante, Felice, Gasbarrini, Antonio, Goldberg, Shraga Nahum, Jakobs, Tobias, Pompili, Maurizio, Bargellini, Irene, Sala, Evis, and Kim, Hyo-Cheol
- Subjects
RADIOEMBOLIZATION ,MINIMALLY invasive procedures ,INTERVENTIONAL radiology ,CHEMOEMBOLIZATION ,TUMOR classification ,MEDICAL protocols ,HEPATOCELLULAR carcinoma ,ABLATION techniques - Abstract
Simple Summary: The aim of this review is to evaluate the different approaches to early-stage hepatocellular carcinoma according to Western and Eastern interventional radiology perspectives based on the most recent literature. Understanding different perspectives and guidelines can help in selecting the correct indication of locoregional procedures (mostly ablation, chemoembolization, and radioembolization) for every patient. Hepatocellular carcinoma represents an important cause of death worldwide. Early-stage hepatocellular carcinoma patients not suitable for surgery can be treated with a variety of minimally invasive locoregional interventional oncology techniques. Various guidelines in different countries address the treatment of hepatocellular carcinoma, but the actual treatment is usually discussed by a multidisciplinary tumor board in a personalized manner, leading to potential treatment differences based on Western and Eastern perspectives. The aim of this paper is to integrate literature evidence with the eminent experiences collected during a focused session at the Mediterranean Interventional Oncology (MIO) Live Congress 2023. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Efficacy of Lymph Node Location-Number Hybrid Staging System on the Prognosis of Gastric Cancer Patients.
- Author
-
Wu, Junpeng, Wang, Hao, Yin, Xin, Wang, Xibo, Wang, Yufei, Lu, Zhanfei, Zhang, Jiaqi, Zhang, Yao, and Xue, Yingwei
- Subjects
STOMACH tumors ,LYMPH nodes ,TUMOR classification ,CANCER patients ,RESEARCH funding ,RECEIVER operating characteristic curves ,LONGITUDINAL method - Abstract
Simple Summary: Lymph node staging is very important for the prognosis of patients with gastric cancer. Currently, the internationally accepted lymph node staging method is the 8th AJCC staging, which divides lymph nodes into different stages according to the number of positive lymph nodes. This staging method is simple and convenient, but ignores the laterality of lymph nodes. In this paper, we for the first time combined the location and number information of positive lymph nodes to create a novel lymph node staging system for gastric cancer. After training cohort and validation cohort tests, this staging is more accurate in predicting the prognosis of patients than the 8th AJCC staging. Background: Lymph node metastasis location and number significantly affects the prognosis of patients with gastric cancer (GC). This study was designed to examine a new lymph node hybrid staging (hN) system to increase the predictive ability for patients with GC. Methods: This study analyzed the gastrointestinal treatment of GC at the Harbin Medical University Cancer Hospital from January 2011 to December 2016, and selected 2598 patients from 2011 to 2015 as the training cohort (hN) and 756 patients from 2016 as the validation cohort (2016-hN). The study utilized the receiver operating characteristic curve (ROC), c-index, and decision curve analysis (DCA) to compare the prognostic performance of the hN with the 8th edition of AJCC pathological lymph node (pN) staging for GC patients. Results: The ROC verification of the training cohort and validation cohort based on each hN staging and pN staging showed that for each N staging, the hN staging had a training cohort with an AUC of 0.752 (0.733, 0.772) and a validation cohort with an AUC of 0.812 (0.780, 0.845). In the pN staging, the training cohort had an AUC of 0.728 (0.708, 0.749), and the validation cohort had an AUC of 0.784 (0.754, 0.824). c-Index and DCA also showed that hN staging had a higher prognostic ability than pN staging, which was confirmed in the training cohort and the verification cohort, respectively. Conclusion: Lymph node location-number hybrid staging can significantly improve the prognosis of patients with GC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Pediatric Extra-Renal Nephroblastoma (Wilms' Tumor): A Systematic Case-Based Review.
- Author
-
Karim, Akzhol, Shaikhyzada, Kundyz, Abulkhanova, Nazgul, Altyn, Akzhunis, Ibraimov, Bakytkali, Nurgaliyev, Dair, and Poddighe, Dimitri
- Subjects
ONLINE information services ,SYSTEMATIC reviews ,SPINA bifida ,NEPHROBLASTOMA ,TREATMENT effectiveness ,CHEMORADIOTHERAPY ,TUMOR classification ,TUMORS in children ,DESCRIPTIVE statistics ,RESEARCH funding ,COMBINED modality therapy ,DEVELOPING countries ,MEDLINE ,SPINAL tumors ,CHILDREN - Abstract
Simple Summary: Wilms tumor (WT) is a rare form of cancer that typically affects children and is usually confined to the kidneys. Extra-renal Wilms tumor (ERWT) is even rarer and develops in other areas of the body, such as the retroperitoneum and inguinal regions, and occasionally at the level of the spinal cord. We present a case report of a 4-year-old boy diagnosed with spinal ERWT, who was also affected with a spinal dysraphism. Our case-based systematic review of pediatric ERWT showed that a multimodal therapeutic approach (including surgery, chemotherapy, and radiotherapy) is important, but an international standardization of the staging approach and therapeutic protocols is needed to define the best clinical management in these children: indeed, there is a lack of clinical studies focused on pediatric ERWT and international trials are needed to achieve these objectives. Our research emphasizes the importance of timely diagnosis and treatment and, possibly, standardized medical approach, in order to improve the outcome of these very rare pediatric malignancies, whose clinical management is even more problematic in developing countries. Wilms Tumor (WT) is one of the most common renal tumors in the pediatric population. Occasionally, WT can primarily develop outside the kidneys (Extra-Renal Wilms Tumor, ERWT). Most pediatric ERWTs develop in the abdominal cavity and pelvis, whereas the occurrence of this tumor in other extra-renal sites represents a minor part of ERWT cases. In addition to describing a case of spinal ERWT (associated with spinal dysraphism) in a 4-year boy (to add a further clinical experience on this very rare pediatric tumor), we performed a case-based systematic literature review on pediatric ERWT. We retrieved 72 papers providing enough information on the diagnosis, treatment, and outcomes of 98 ERWT pediatric patients. Our research highlighted that a multimodal approach involving both chemotherapy and radiotherapy, after partial or complete tumor resection in most cases, was typically used, but there is no standardized therapeutic approach for this pediatric malignancy. However, this tumor may be potentially treated with a better success rate if the diagnostic confirmation is not delayed, the mass can be totally resected, and an appropriate and, possibly, tailored multimodal treatment can be promptly established. In this regard, an international agreement on a unique staging system for (pediatric) ERWT is definitely needed, as well as the development of international research, which may be able to gather several children diagnosed with ERWT and, possibly, lead to clinical trials which should also include developing countries. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines.
- Author
-
Restaino, Stefano, Paglietti, Chiara, Arcieri, Martina, Biasioli, Anna, Della Martina, Monica, Mariuzzi, Laura, Andreetta, Claudia, Titone, Francesca, Bogani, Giorgio, Raimondo, Diego, Perelli, Federica, Buda, Alessandro, Petrillo, Marco, Greco, Pantaleo, Ercoli, Alfredo, Fanfani, Francesco, Scambia, Giovanni, Driul, Lorenza, and Vizzielli, Giuseppe
- Subjects
MEDICAL protocols ,MOLECULAR biology ,TUMOR classification ,ENDOMETRIAL tumors ,HEALTH equity ,TUMORS - Abstract
Simple Summary: Endometrial cancer has a high epidemiological impact, and its management is part of everyday clinical practice. International guidelines have been arranged over the years according to major recent discoveries. The application of the guidelines released by different international gynecological societies is still matter of debate as they diverge in many issues. Authors wanted to compare them and point out the differences, aiming to both draw the attention to a need of unification and to provide a useful tool for clinicians. Endometrial cancer is the most common gynecological malignancy in Europe and its management involves a variety of health professionals. In recent years, big discoveries were made concerning the management of patients diagnosed with endometrial cancer, particularly in the field of molecular biology and minimally invasive surgery. This requires the continuous updating of guidelines and protocols over the years. In this paper, we aim to summarize and compare common points and disparities among protocols for management of patients diagnosed with endometrial cancer by leading international gynecological oncological societies. We therefore systematically report the parallel among the guidelines based on the various steps patients with endometrial cancer usually undergo. The comparison between American and European protocols revealed some relevant disparities, in particular regarding surgical staging, molecular biology application as a prognostic tool and follow up regimens. This could possibly cause differences in interpreting and applying protocols in clinical practice in small centers, leading to a lack of adherence to guidelines or even prompting a confusing mix of them. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice.
- Author
-
Fanotto, Valentina, Salani, Francesca, Vivaldi, Caterina, Scartozzi, Mario, Ribero, Dario, Puzzoni, Marco, Montagnani, Francesco, Leone, Francesco, Vasile, Enrico, Bencivenga, Maria, De Manzoni, Giovanni, Basile, Debora, Fornaro, Lorenzo, Masi, Gianluca, and Aprile, Giuseppe
- Subjects
PANCREATIC tumors ,ADENOCARCINOMA ,METASTASIS ,COLORECTAL cancer ,GASTROINTESTINAL tumors ,TUMOR classification ,TREATMENT effectiveness ,QUALITY of life ,HEALTH care teams ,OVERALL survival - Abstract
Simple Summary: Oncology practice in gastrointestinal tumors is moving toward therapeutic algorithms comprising multiple systemic options integrated with loco-regional strategies, such as surgery. This paradigm holds true for metastatic colorectal cancer, as well as upper gastrointestinal neoplasms, where the role of the resection of the primary tumor, with or without the administration of systemic therapies and metastasectomy, has been a matter of debate. In our review paper, we discuss the available randomized and retrospective evidence supporting surgery in the metastatic setting of colorectal, gastric and pancreatic cancers, with the aim to grant the clinicians with an up-to-date state of the art on this subject. The management of the primary tumor in metastatic colorectal, gastric and pancreatic cancer patients may be challenging. Indeed, primary tumor progression could be associated with severe symptoms, compromising the quality of life and the feasibility of effective systemic therapy, and might result in life-threatening complications. While retrospective series have suggested that surgery on the primary tumor may confer a survival advantage even in asymptomatic patients, randomized trials seem not to definitively support this hypothesis. We discuss the evidence for and against primary tumor resection for patients with metastatic gastrointestinal (colorectal, gastric and pancreatic) cancers treated with systemic therapies and put in context the pros and cons of the onco-surgical approach in the time of precision oncology. We also evaluate current ongoing trials on this topic, anticipating how these will influence both research and everyday practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Editorial: Recent Advances in Deep Learning and Medical Imaging for Cancer Treatment.
- Author
-
Ijaz, Muhammad Fazal and Woźniak, Marcin
- Subjects
TUMOR treatment ,TUMOR diagnosis ,TUMOR classification ,DEEP learning ,SERIAL publications ,DIAGNOSTIC imaging ,AUTOMATION ,COMPUTER-assisted image analysis (Medicine) - Published
- 2024
- Full Text
- View/download PDF
32. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET.
- Author
-
Sabbagh, Ali, Mohamad, Osama, Lichter, Katie E., and Hope, Thomas A.
- Subjects
BIOCHEMISTRY ,PHENOMENOLOGICAL biology ,CANCER relapse ,EARLY detection of cancer ,CANCER patients ,TUMOR classification ,POSITRON emission tomography ,PROSTATE-specific membrane antigen ,SENSITIVITY & specificity (Statistics) ,RADIOTHERAPY ,PROSTATE tumors ,DISEASE management - Abstract
Simple Summary: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a modern imaging modality used in the management of patients with prostate cancer with improved accuracy in detecting lymph nodes and distant disease spread. In this paper, we discuss how the increasing use of PSMA PET is changing clinical management in patients with prostate cancer, specifically those previously treated for localized disease and now presenting with recurrence or low-volume metastatic disease spread. We also discuss how PSMA PET is affecting clinical trial design and interpretation. More clinical trials are needed to investigate whether the use of PSMA PET translates into improved patient survival or quality of life. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans have higher sensitivity and specificity for detecting lymph nodes or metastatic disease relative to conventional imaging in prostate cancer staging. Since its FDA approval and incorporation into treatment guidelines, the use of PSMA PET has increased in patients undergoing initial staging, those with recurrence after initial definitive treatment, and patients with metastatic disease. Although the early detection of metastatic lesions is changing disease management, it is unclear whether this impact on management translates into clinical benefit. This review will summarize evidence pertaining to the change in patient management due to PSMA PET use and will discuss the implications of PSMA PET on treatment decisions in prostate cancer, particularly in the settings of biochemical recurrence and metachronous oligometastatic disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Challenges in the Early Diagnosis of Oral Cancer, Evidence Gaps and Strategies for Improvement: A Scoping Review of Systematic Reviews.
- Author
-
González-Moles, Miguel Ángel, Aguilar-Ruiz, Manuel, and Ramos-García, Pablo
- Subjects
ONLINE information services ,MEDICAL databases ,MOUTH tumors ,MEDICAL information storage & retrieval systems ,SYSTEMATIC reviews ,EVIDENCE gaps ,TUMOR classification ,LITERATURE reviews ,MEDLINE ,EARLY diagnosis - Abstract
Simple Summary: Oral cancer presents a worldwide incidence of 377,713 new cases and 177,757 deaths per year (GLOBOCAN, IARC, WHO). Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of oral malignancies and has a 5-year mortality rate close to 50%. We aim to better understand, based on the evidence, and to discuss in depth, the reasons for the diagnostic delay of oral cancer by reviewing systematic reviews and meta-analyses. We also aim to, identify gaps in evidence, recommend future lines of research that should be implemented, and formulate strategies for improvement. Oral cancer is a growing problem, accounting for 377,713 worldwide new cases per year, and 177,757 deaths annually and representing a 5-year mortality rate close to 50%, which is a considerable mortality that has not decreased substantially in the last 40 years. The main cause of this high mortality is related to the diagnosis of a high percentage of oral cancers in advanced stages (stages III and IV) in which treatment is complex, mutilating or disabling, and ineffective. The essential cause of a cancer diagnosis at a late stage is the delay in diagnosis, therefore, the achievement of the objective of improving the prognosis of oral cancer involves reducing the delay in its diagnosis. The reasons for the delay in the diagnosis of oral cancer are complex and involve several actors and circumstances—patients, health care providers, and health services. In this paper, we present the results of a scoping review of systematic reviews on the diagnostic delay in oral cancer with the aim to better understand, based on the evidence, and discuss in depth, the reasons for this fact, and to identify evidence gaps and formulate strategies for improvement. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Reconstructive Surgery versus Primary Closure following Vulvar Cancer Excision: A Wide Single-Center Experience.
- Author
-
Muallem, Mustafa Zelal, Sehouli, Jalid, Miranda, Andrea, Plett, Helmut, Sayasneh, Ahmad, Diab, Yasser, Muallem, Jumana, and Hatoum, Imad
- Subjects
WOUND healing ,VULVECTOMY ,VULVAR tumors ,PLASTIC surgery ,RETROSPECTIVE studies ,ACQUISITION of data ,TREATMENT effectiveness ,TUMOR classification ,SEVERITY of illness index ,DISEASE relapse ,MEDICAL records ,DESCRIPTIVE statistics ,COMORBIDITY ,EVALUATION - Abstract
Simple Summary: When it comes to advanced vulval cancer management, there is a critical quandary to consider. This is owing to the severe negative impact of demolitive surgery on women who are afflicted by both functional and psychological consequences of the procedure. Primary closure of vulvar and/or perineal defects can be accomplished without difficulty in many situations, but this is accompanied by tension of the skin closure and distortion of the anatomy. In these circumstances, reconstructive surgery will be required to restore the anatomical and functional characteristics of the vulva. In this paper, we share our substantial expertise of primary closure versus reconstruction after demolitive surgery of advanced vulvar cancer, and we discuss our findings in light of the literature. (1) Background: plastic reconstruction in vulvar surgery can lead to a better treatment outcome than primary closure. This study aims to compare the preoperative parameters (co-morbidities and tumor size) and postoperative results (tumor free margins and wound healing) between the primary closure and reconstructive surgery after vulvar cancer surgery; (2) Methods: this is a retrospective analysis of prospectively collected data from 2009 to 2021 at a tertiary cancer institution; (3) Results: 177 patients were included in the final analysis (51 patients had primary closure PC and 126 had reconstructive surgery RS). About half (49%) of the PC patients had no co-morbidities (p = 0.043). The RS group had a 45 mm median maximal tumor diameter compared to the PC group's 23 mm (p = 0.013). More than 90% of RS and 80% of PC had tumor-free margins (p = 0.1). Both groups had anterior vulvar excision as the most common surgery (52.4% RS vs. 23.5% PC; p = 0.001). Both groups had identical rates of wound healing disorders. In a median follow-up of 39 months; recurrent disease was found in 23.5% of PC vs. 10.3% in RS (p = 0.012). In terms of overall survival there was no significant difference between the both groups; (4) Conclusions: reconstructive vulvar surgery enables enhanced complete resection rates of larger vulvar tumors with better anatomical restoration and a comparable wound recovery in comparison to primary closure. This results in a lower recurrence rate despite the increased tumor volume. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Unveiling Insights into Ovarian Cancer Metabolism through Space- and Time-Resolved Analysis.
- Author
-
Jia, Wei and Li, Mengci
- Subjects
DISEASE progression ,OVARIAN tumors ,METABOLOMICS ,LIQUID chromatography ,EARLY detection of cancer ,TUMOR classification ,GENOMICS ,MASS spectrometry ,TUMORS ,TUMOR markers - Published
- 2023
- Full Text
- View/download PDF
36. Derived Neutrophils to Lymphocyte Ratio Predicts Survival Benefit from TPF Induction Chemotherapy in Local Advanced Oral Squamous Cellular Carcinoma.
- Author
-
Zhu, Fangxing, Zhou, Xinyu, Zhang, Yiyi, Zhou, Zhihang, Huang, Yingying, Zhong, Laiping, Zhao, Tongchao, and Yang, Wenjun
- Subjects
THERAPEUTIC use of antineoplastic agents ,NEUTROPHIL lymphocyte ratio ,SQUAMOUS cell carcinoma ,DOCETAXEL ,REFERENCE values ,CISPLATIN ,CANCER relapse ,RECEIVER operating characteristic curves ,RESEARCH funding ,MULTIVARIATE analysis ,CANCER patients ,CHI-squared test ,KAPLAN-Meier estimator ,FLUOROURACIL ,TUMOR classification ,CONFIDENCE intervals ,PROGRESSION-free survival ,INDUCTION chemotherapy ,PROPORTIONAL hazards models ,PATIENT aftercare ,OVERALL survival ,EVALUATION - Abstract
Simple Summary: This study aimed to evaluate the derived neutrophil to lymphocyte ratio (dNLR) in predicting the prognosis of patients with locally advanced oral squamous cell carcinoma, as well as the survival benefits from induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU). The dNLR is an independent negative predictive factor for the disease. Patients with cTNM stage III disease and a low dNLR may benefit from induction chemotherapy. Background: This study aimed to evaluate the derived neutrophil to lymphocyte ratio (dNLR) in predicting the prognosis of patients with locally advanced oral squamous cell carcinoma (LAOSCC) and to assess the survival benefits from docetaxel, cisplatin, and 5-fluorouracil (5-FU) (TPF) induction chemotherapy (IC). Methods: Patients from a phase III trial involving TPF IC in stage III/IVA OSCC patients (NCT01542931) were enrolled. Receiver operating characteristic curves were constructed, and the area under the curve was computed to determine dNLR cutoff points. Kaplan–Meier survival estimates and Cox proportional hazards models were used for longitudinal analysis. Results: A total of 224 patients were identified (median age: 55.4 years; range: 26 to 75 years; median follow-up: 90 months; range: 3.2 to 93 months). The cutoff point for the dNLR was 1.555. Multivariate analysis showed that the dNLR was an independent negative predictive factor for survival (overall survival (OS): hazard ratio (HR) = 1.154, 95% confidence interval (CI): 1.018–1.309, p = 0.025; disease-free survival (DFS): HR = 1.123, 95% CI: 1.000–1.260, p = 0.050; local recurrence-free survival (LRFS): HR = 1.134, 95% CI: 1.002–1.283, p = 0.047; distant metastasis-free survival (DMFS): HR = 1.146, 95% CI: 1.010–1.300, p = 0.035). A low dNLR combined with cTNM stage III disease predicted benefit from TPF IC for the patients [OS (χ
2 = 4.674, p = 0.031), DFS (χ2 = 7.134, p = 0.008), LRFS (χ2 = 5.937, p = 0.015), and DMFS (χ2 = 4.832, p = 0.028)]. Conclusions: The dNLR is an independent negative predictive factor in LAOSCC patients. Patients with cTNM stage III disease and a low dNLR can benefit from TPF IC. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
37. Performance of Contrast-Enhanced Mammography (CEM) for Monitoring Neoadjuvant Chemotherapy Response among Different Breast Cancer Subtypes.
- Author
-
Vidali, Sofia, Irmici, Giovanni, Depretto, Catherine, Bellini, Chiara, Pugliese, Francesca, Incardona, Ludovica Anna, Di Naro, Federica, De Benedetto, Diego, Di Filippo, Giacomo, Ferraro, Fabiola, De Berardinis, Claudia, Miele, Vittorio, Scaperrotta, Gianfranco, and Nori Cucchiari, Jacopo
- Subjects
HORMONES ,BREAST tumors ,POLYMERASE chain reaction ,TREATMENT effectiveness ,RETROSPECTIVE studies ,TERTIARY care ,CANCER patients ,DESCRIPTIVE statistics ,ADJUVANT chemotherapy ,IODINE compounds ,GENES ,COMBINED modality therapy ,MAMMOGRAMS ,ONCOGENES ,DRUG efficacy ,TUMOR classification ,CONTRAST media ,SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: The indications for neoadjuvant chemotherapy (NAT) have expanded in recent years both for locally advanced and early-stage breast cancer, with different pathological complete response (pCR) rates among different molecular subtypes. This retrospective two-center study aims to evaluate the diagnostic performance of Contrast-Enhanced Mammography (CEM) in assessing the response to NAT in breast cancer patients. The CEM sensitivity and specificity were 66.2% and 75.2%, with the highest specificity (80.9%) in HR+/HER2− and the highest sensitivity (70%) in triple-negative breast cancer. CEM is a valid tool to assess the pCR with different performances among the molecular subtypes and may be reliable in the decisional process of de-escalating surgical management. Neoadjuvant chemotherapy (NAT) plays a crucial role in breast cancer (BC) treatment, both in advanced BC and in early-stage BC, with different rates of pathological complete response (pCR) among the different BC molecular subtypes. Imaging monitoring is mandatory to evaluate the NAT efficacy. This study evaluates the diagnostic performance of Contrast-Enhanced Mammography (CEM) in BC patients undergoing NAT. This retrospective two-center study included 174 patients. The breast lesions were classified based on the molecular subtypes in hormone receptor (HR+)/HER2−, HER2+, and triple-negative breast cancer (TNBC). The histopathological analysis performed following surgery was used as a reference standard for the pCR. Sensitivity, specificity, PPV, and NPV were measured overall and for the different subtypes. We enrolled 174 patients, 79/174 (46%) HR+/HER2−, 59/174 (33.9%) HER2+, and 35/174 (20.1%) TNBC; the pCR was found in 64/174 (36.8%), of which 57.1% were TNBCs. In the total population, the CEM sensitivity and specificity were 66.2% and 75.2%, with a PPV of 61.4% and an NPV of 78.8%. The highest specificity (80.9%) and NPV (91.7%) were found in HR+/HER2−, while the highest sensitivity (70%) and PPV appeared (73.7%) in TNBC. The results indicate that CEM is a valid tool to assess the pCR, with different performances among the subtypes of BC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment.
- Author
-
Lee, Hyun Joo, Choi, Moon Seok, Song, Byeong Geun, Kang, Won Seok, Gwak, Geum Youn, Goh, Myung Ji, Paik, Yong Han, Lee, Joon Hyeok, and Sinn, Dong Hyun
- Subjects
STATISTICAL correlation ,CANCER relapse ,GLYCOSYLATED hemoglobin ,TREATMENT effectiveness ,CANCER patients ,DESCRIPTIVE statistics ,BLOOD sugar ,DOSE-effect relationship in pharmacology ,RESEARCH ,TUMOR classification ,CONFIDENCE intervals ,HEPATOCELLULAR carcinoma ,OVERALL survival ,DISEASE risk factors - Abstract
Simple Summary: Early-stage hepatocellular carcinoma (HCC) is notorious for its high recurrence rate even after curative treatment. Several studies have suggested the association between diabetes mellitus (DM) and the risk of HCC. However, current evidence regarding the impact of glycemic burden on the outcomes of HCC is still limited. The present study provides an important insight into the relationship between glycemic burden and outcomes of early-stage HCC. Lower glycemic burden was an independent factor associated with better overall survival as well as lower recurrence in early-stage HCC. Moreover, there was a dose–response relationship between recurrence/overall survival and glycemic burden. Good glycemic control should be considered as a significant part of HCC management. Early-stage hepatocellular carcinoma (HCC) is still difficult to cure for its high recurrence rate. This study aimed to examine whether glycemic burden management could be one way to improve outcomes of early-stage HCC. A total of 137 very early or early-stage HCC patients who underwent resection or ablation at Samsung Medical Center and had glycemic burden assessment were analyzed. Glycemic burden was assessed using hemoglobin A1c (HbA1c) level. Outcomes were recurrence and overall survival. Risks of recurrence and overall survival were compared according to glycemic burden using a cut-off point of 6.5% or two cut-off points of 6.0% and 7.5%. Overall, 51 (37.2%) patients experienced HCC recurrence. The adjusted hazard ratio (aHR) for recurrence comparing patients with HbA1c > 6.5% to those with HbA1c ≤ 6.5% was 2.66 (95% CI: 1.26–5.78). The risk of recurrence increased in a dose-dependent manner by glycemic burden; aHR for 6.0 < HbA1c ≤ 7.5%: 2.00 (95% CI: 0.78–5.55); aHR for HbA1c > 7.5%: 6.05 (95% CI: 2.31–17.5). Mortality was observed in 16 (11.7%) patients. The risk of mortality was higher for HbA1c > 6.5% than for HbA1c ≤ 6.5% (aHR: 2.33; 95% CI: 1.10–5.08). There was also a dose–response relationship between overall survival and glycemic burden. Glycemic burden assessed using HbA1c level was significantly associated with outcomes of early-stage HCC patients. Good glycemic control could be a therapeutic goal to improve clinical outcomes in these populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Multiparametric Whole-Body MRI: A Game Changer in Metastatic Prostate Cancer.
- Author
-
Cattabriga, Arrigo, Renzetti, Benedetta, Galuppi, Francesco, Bartalena, Laura, Gaudiano, Caterina, Brocchi, Stefano, Rossi, Alice, Schiavina, Riccardo, Bianchi, Lorenzo, Brunocilla, Eugenio, Spinozzi, Luca, Catanzaro, Calogero, Castellucci, Paolo, Farolfi, Andrea, Fanti, Stefano, Tunariu, Nina, and Mosconi, Cristina
- Subjects
PROSTATE tumors treatment ,RISK assessment ,CANCER relapse ,DIAGNOSTIC imaging ,EARLY detection of cancer ,RADIOLOGIC technology ,PROSTATE tumors ,MAGNETIC resonance imaging ,TREATMENT effectiveness ,POSITRON emission tomography computed tomography ,METASTASIS ,NUCLEAR medicine ,TUMOR classification ,RADIONUCLIDE imaging ,CONTRAST media ,EVALUATION ,DISEASE risk factors - Abstract
Simple Summary: In the realm of next-generation imaging, whole-body MRI (WB-MRI) is evolving as a key player in the modern management of patients with prostate cancer, showing great potential in the initial staging of high-risk disease, post-treatment evaluation, and recurrence assessment. This technique showcases both notable agreement and complementarity with PET/CT, particularly in identifying secondary bone, nodal, and visceral lesions. WB-MRI's strength lies in its "one size fits all" nature, avoiding contrast agents and radiotracers and adapting to diverse patient needs. Leveraging DWI and rFF%, it excels in bone metastasis detection, offering a comprehensive view. With promising potential for precise response assessment, WB-MRI emerges as a transformative tool in the management of metastatic prostate cancer. Prostate cancer ranks among the most prevalent tumours globally. While early detection reduces the likelihood of metastasis, managing advanced cases poses challenges in diagnosis and treatment. Current international guidelines support the concurrent use of
99 Tc-Bone Scintigraphy and Contrast-Enhanced Chest and Abdomen CT for the staging of metastatic disease and response assessment. However, emerging evidence underscores the superiority of next-generation imaging techniques including PSMA-PET/CT and whole-body MRI (WB-MRI). This review explores the relevant scientific literature on the role of WB-MRI in metastatic prostate cancer. This multiparametric imaging technique, combining the high anatomical resolution of standard MRI sequences with functional sequences such as diffusion-weighted imaging (DWI) and bone marrow relative fat fraction (rFF%) has proved effective in comprehensive patient assessment, evaluating local disease, most of the nodal involvement, bone metastases and their complications, and detecting the increasing visceral metastases in prostate cancer. It does have the advantage of avoiding the injection of contrast medium/radionuclide administration, spares the patient the exposure to ionizing radiation, and lacks the confounder of FLARE described with nuclear medicine techniques. Up-to-date literature regarding the diagnostic capabilities of WB-MRI, though still limited compared to PSMA-PET/CT, strongly supports its widespread incorporation into standard clinical practice, alongside the latest nuclear medicine techniques. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. High M2-TAM Infiltration and STAT3/NF-κB Signaling Pathway as a Predictive Factor for Tumor Progression and Death in Cervical Cancer.
- Author
-
Lira, George Alexandre, de Azevedo, Fábio Medeiros, Lins, Ingrid Gabrielle dos Santos, Marques, Isabelle de Lima, Lira, Giovanna Afonso, Eich, Christina, and de Araujo Junior, Raimundo Fernandes
- Subjects
NF-kappa B ,TISSUE arrays ,CERVIX uteri tumors ,CANCER relapse ,RESEARCH funding ,CELL physiology ,MULTIPLE regression analysis ,TUMOR markers ,CELLULAR signal transduction ,TRANSCRIPTION factors ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,LONGITUDINAL method ,IMMUNOHISTOCHEMISTRY ,KAPLAN-Meier estimator ,SURVIVAL analysis (Biometry) ,TUMOR classification ,DATA analysis software ,DISEASE progression ,OVERALL survival ,PROPORTIONAL hazards models - Abstract
Simple Summary: Once in an immunosuppressive tumoral microenvironment (TME), macrophages take over an essential role by activating signaling pathways such as STAT3 and NFkB to keep the immune suppression and tumor progression. However, this role in cancer cervical (CC) is not still clear. For that, we studied the interaction of tumor associated macrophages (TAM) and STAT3 and NFkB pathways with of several cancer hallmarks in 691 patients with CC, and more importantly, their impact on clinical outcome of these patients. Interestingly, a strong immunosuppressive loop was identified via TAM and STAT3 and NFkB pathways in TME which reverberated in a higher expression of tumor progression markers, and consequently in a poor clinical outcome. Introduction: The tumor microenvironment (TME) plays a crucial role in the progression, invasion, and metastasis of cervical carcinoma (CC). Tumor-associated macrophages (TAMs) are significant components of the CC TME, but studies on their correlation with CC progression are still controversial. This study aimed to investigate the relationship between TAM infiltration, the STAT3/NF-κB signaling pathway, and Overall Survival (OS) in CC patients. Methods: In a retrospective study, 691 CC patients who had received a definitive histopathologic diagnosis of CC scored by the FIGO staging system and not undergone preoperative treatment were selected from a database. The effect of TAM infiltration on tumor progression biomarkers using Tissue Microarray (TMA) and immunohistochemistry was evaluated. Furthermore, the impact of the expression of these biomarkers and clinical–pathological parameters on recurrence-free (RF) and OS using Kaplan–Meier and multivariable Cox regression methods was also analyzed. Results: High stromal CD163 + 204 + TAMs density and via STAT3 and NF-κB pathways was relevant to the expression of E-cadherin, Vimentin, MMP9, VEGFα, Bcl-2, Ki-67, CD25, MIF, FOXP3, and IL-17 (all p < 0.0001). In addition, elevated TNM staging IV had a strong association correlation with STAT3 and NF-κB pathways (p < 0.0001), CD25 (p < 0.001), VEGFα (p < 0.001), MIF (p < 0.0001), and Ki-67 (p < 0.0001). On the other hand, overall and recurrence survival was shown to be strongly influenced by the expression of SNAIL (HR = 1.52), E-cadherin (HR = 1.78), and Ki-67 (HR = 1.44). Conclusion: M2-TAM and via STAT3/NF-κB pathways had a strong effect on CC tumor progression which reverberated in the severity of clinicopathological findings, becoming an important factor of poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches.
- Author
-
Reitano, Giuseppe, Ceccato, Tommaso, Botti, Simone, Bruniera, Martina, Carrozza, Salvatore, Bovolenta, Eleonora, Randazzo, Gianmarco, Minardi, Davide, Ruggera, Lorenzo, Gardi, Mario, Novara, Giacomo, Dal Moro, Fabrizio, and Zattoni, Fabio
- Subjects
RISK assessment ,CANCER relapse ,LYMPHADENECTOMY ,DIFFUSION of innovations ,RADIOTHERAPY ,RADICAL prostatectomy ,ARTIFICIAL intelligence ,PROSTATE tumors ,TREATMENT effectiveness ,POSITRON emission tomography ,COMBINED modality therapy ,PROSTATE-specific membrane antigen ,TUMOR classification ,INDIVIDUALIZED medicine ,MACHINE learning ,PERIOPERATIVE care ,DISEASE progression ,EVALUATION ,DISEASE risk factors - Abstract
Simple Summary: High-risk prostate cancer is an aggressive disease, and its treatment can be complex and require the involvement of several specialists. Advances in imaging and therapies in this field can improve survival and help physicians choose the best personalized approach that maintains quality of life. This article summarizes the most recent publications on this condition and its treatments, aiming to provide an updated guide for managing patients with prostate cancer who experience a higher risk of progression and death. The management of high-risk prostate cancer (PCa) presents a significant clinical challenge, often necessitating treatment intensification due to the potential presence of micrometastases. While radical prostatectomy (RP) constitutes one of the primary treatment modalities, the integration of neoadjuvant and adjuvant therapies suggests a paradigm shift towards more aggressive treatment strategies, also guided by new imaging modalities like positron emission tomography using prostate-specific membrane antigen (PSMA-PET). Despite the benefits, treatment intensification raises concerns regarding increased side effects. This review synthesizes the latest evidence on perioperative treatment intensification and de-escalation for high-risk localized and locally advanced PCa patients eligible for surgery. Through a non-systematic literature review conducted via PubMed, Scopus, Web of Science, and ClinicalTrials.gov, we explored various dimensions of perioperative treatments, including neoadjuvant systemic therapies, adjuvant therapies, and the role of novel diagnostic technologies. Emerging evidence provides more support for neoadjuvant systemic therapies. Preliminary results from studies suggest the potential for treatments traditionally reserved for metastatic PCa to show apparent benefit in a non-metastatic setting. The role of adjuvant treatments remains debated, particularly the use of androgen deprivation therapy (ADT) and adjuvant radiotherapy in patients at higher risk of biochemical recurrence. The potential role of radio-guided PSMA lymph node dissection emerges as a cutting-edge approach, offering a targeted method for eradicating disease with greater precision. Innovations such as artificial intelligence and machine learning are potential game-changers, offering new avenues for personalized treatment and improved prognostication. The intensification of surgical treatment in high-risk PCa patients is a dynamic and evolving field, underscored by the integration of traditional and novel therapeutic approaches. As evidence continues to emerge, these strategies will refine patient selection, enhance treatment efficacy, and mitigate the risk of progression, although with an attentive consideration of the associated side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease.
- Author
-
Falo, Catalina, Azcarate, Juan, Fernandez-Gonzalez, Sergi, Perez, Xavier, Petit, Ana, Perez, Héctor, Vethencourt, Andrea, Vazquez, Silvia, Laplana, Maria, Ales, Miriam, Stradella, Agostina, Fullana, Bartomeu, Pla, Maria J., Gumà, Anna, Ortega, Raul, Varela, Mar, Pérez, Diana, Ponton, Jose Luis, Cobo, Sara, and Benitez, Ana
- Subjects
THERAPEUTIC use of antineoplastic agents ,BREAST tumor treatment ,BREAST tumors ,CANCER patients ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,CANCER chemotherapy ,LONGITUDINAL method ,KAPLAN-Meier estimator ,LOG-rank test ,COMBINED modality therapy ,TUMOR classification ,SURVIVAL analysis (Biometry) ,EVALUATION - Abstract
Simple Summary: Neoadjuvant chemotherapy in breast cancer facilitates breast and axillary surgery and offers significant prognostic value. We present a retrospective cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHER2 in HER2-positive cases. The 10-year estimated disease free survival was 77.3% (95%CI 73.3–81.4%) and the Breast cancer specific survival 83.7% (95%CI 80.3–87.2%). The statistically independent factors related to patient survival were pathology subtype (lobular cancers HR, 4); molecular surrogate subtype (triple negative HR, 4); type of surgery (mastectomy HR, 2), response to chemotherapy (the risk incremented according to the residual cancer burden in 2.2, 4.4 and 8.0 times in I, II and III, respectively) and vascular invasion (HR, 2.4). BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions. Introduction: Neoadjuvant chemotherapy in breast cancer offers the possibility to facilitate breast and axillary surgery; it is a test of chemosensibility in vivo with significant prognostic value and may be used to tailor adjuvant treatment according to the response. Material and Methods: A retrospective single-institution cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHEr2 in Her2-positive cases, was studied. Survival was calculated at 5 and 10 years. Kaplan–Meier curves with a log-rank test were calculated for differences according to age, BRCA status, menopausal status, TNM, pathological and molecular surrogate subtype, 20% TIL cut-off, surgical procedure, response to chemotherapy and the presence of vascular invasion. Results: The pCR rate was 25.3% and was greater in HER2 (51.3%) and TNBC (31.7%) and in BRCA carriers (41.9%). The factors independently related to patient survival were pathology and molecular surrogate subtype, type of surgery, response to NACT and vascular invasion. BRCA status was a protective prognostic factor without reaching statistical significance, with an HR 0.5 (95%CI 0.1–1.4). Mastectomy presented a double risk of distant recurrence compared to breast-conservative surgery (BCS), supporting BCS as a safe option after NACT. After a mean follow-up of 126 (SD 43) months, luminal tumors presented a substantial difference in survival rates calculated at 5 or 10 years (81.2% compared to 74.7%), whereas that for TNBC was 75.3 and 73.5, respectively. The greatest difference was seen according to the response in patients with pCR, who exhibited a 10 years DDFS of 95.5% vs. 72.4% for those patients without pCR, p < 0001. This difference was especially meaningful in TNBC: the 10 years DDFS according to an RCB of 0 to 3 was 100%, 80.6%, 69% and 49.2%, respectively, p < 0001. Patients with a particularly poor prognosis were those with lobular carcinomas, with a 10 years DDFS of 42.9% vs. 79.7% for ductal carcinomas, p = 0.001, and patients with vascular invasion at the surgical specimen, with a 10 years DDFS of 59.2% vs. 83.6% for those patients without vascular invasion, p < 0.001. Remarkably, BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Conclusions: Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Variances in the Expression Profile of Circadian Clock-Related Genes in Astrocytic Brain Tumors.
- Author
-
Staszkiewicz, Rafał, Sobański, Dawid, Pulka, Wojciech, Gładysz, Dorian, Gadzieliński, Marcin, Strojny, Damian, and Grabarek, Beniamin Oskar
- Subjects
GLIOMAS ,PROTEIN kinases ,DATA analysis ,T-test (Statistics) ,NEUROGLIA ,MICRORNA ,ENZYME-linked immunosorbent assay ,REVERSE transcriptase polymerase chain reaction ,TUMOR markers ,DESCRIPTIVE statistics ,DNA methylation ,GENE expression profiling ,MICROARRAY technology ,ANALYSIS of variance ,STATISTICS ,CANCER genes ,TUMOR classification ,DATA analysis software ,BRAIN tumors ,DISEASE progression - Abstract
Simple Summary: This study investigates the role of circadian clock genes in the progression of astrocytic tumors, a common type of brain tumor. We aimed to understand how these genes, which control the body's daily rhythms, behave differently in low-grade versus high-grade tumors. Our findings reveal that certain circadian clock genes are more active in advanced tumor stages, potentially driving tumor growth. Additionally, we discovered that changes in DNA methylation and microRNAs might regulate these genes. Understanding these molecular changes could help identify new biomarkers for tumor diagnosis and progression, offering new avenues for targeted treatments. This research provides valuable insights into the complex biology of brain tumors and highlights the importance of circadian genes in the development of cancer. This study explores the role of circadian clock genes in the progression of astrocytic tumors, a prevalent type of brain tumor. The aim was to assess the expression patterns of these genes in relation to the tumor grade. Using microarray analysis, qRT-PCR, and methylation-specific PCR, we examined gene expression, DNA methylation patterns, and microRNA interactions in tumor samples from 60 patients. Our results indicate that the expression of key circadian clock genes, such as clock circadian regulator (CLOCK), protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1), protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2), protein kinase AMP-activated non-catalytic subunit beta 1 (PRKAB1), protein kinase AMP-activated non-catalytic subunit beta 2 (PRKAB2), period circadian regulator 1 (PER1), period circadian regulator 2 (PER2) and period circadian regulator 3 (PER3), varies significantly with the tumor grade. Notably, increased CLOCK gene expression and protein levels were observed in higher-grade tumors. DNA methylation analysis revealed that the promoter regions of PER1-3 genes were consistently methylated, suggesting a mechanism for their reduced expression. Our findings also underscore the complex regulatory mechanisms involving miRNAs, such as hsa-miR-106-5p, hsa-miR-20b-5p, and hsa-miR-30d-3p, which impact the expression of circadian clock-related genes. This underscores the importance of circadian clock genes in astrocytic tumor progression and highlights their potential as biomarkers and therapeutic targets. Further research is needed to validate these results and explore their clinical implications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.
- Author
-
De Mello, Ramon Andrade Bezerra, Voscaboinik, Rafael, Luciano, João Vittor Pires, Cremonese, Rafaela Vilela, Amaral, Giovanna Araujo, Castelo-Branco, Pedro, and Antoniou, Georgios
- Subjects
THERAPEUTIC use of antineoplastic agents ,LUNG cancer ,SURVIVAL ,GENETIC mutation ,IMMUNE checkpoint inhibitors ,CANCER chemotherapy ,ANTINEOPLASTIC agents ,TUMOR classification ,MEMBRANE proteins ,T cells ,VASCULAR endothelial growth factors ,IMMUNOTHERAPY ,ANTIGENS - Abstract
Simple Summary: The following paper was developed as a reference for healthcare workers who are looking for information on advanced non-small cell lung cancers that lack driver mutations and their treatment with immunotherapy. The aim of the present study is to provide a reliable data source based on a review of the most current papers on the PD-1/PD-L1 and CTLA-4 inhibitors, as well as their use in medical practice. From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Topographic Patterns of Intracranial Meningioma Recurrences—Systematic Review with Clinical Implication.
- Author
-
Corvino, Sergio, Altieri, Roberto, La Rocca, Giuseppe, Piazza, Amedeo, Corazzelli, Giuseppe, Palmiero, Carmela, Mariniello, Giuseppe, Maiuri, Francesco, Elefante, Andrea, and de Divitiis, Oreste
- Subjects
CANCER risk factors ,ONCOLOGIC surgery ,TUMOR classification ,MENINGES ,RISK assessment ,MEDICAL information storage & retrieval systems ,CLINICAL medicine ,DECISION making ,MAGNETIC resonance imaging ,EVALUATION of medical care ,SYSTEMATIC reviews ,MEDLINE ,MENINGIOMA ,DISEASE relapse ,DISEASE risk factors - Abstract
Simple Summary: Meningiomas are the most common primary benign tumor of the central nervous system, and, despite their prevalent benign nature, they exhibit variable tendency to recur during the lifetime, even after multiple reoperations, adjuvant radiation treatment and several years, posing a significant challenge of management. While well-defined risk factors of recurrence have been identified, the topographic pattern after surgery has scarcely been investigated. Nevertheless, the possibility of theoretically predicting the site of recurrence provides a significant advantage for a multidisciplinary team during the decision-making process regarding the strategy of treatment at the first surgery. The authors performed a comprehensive and detailed systematic literature review on the topographic pattern of recurrence after surgical treatment for intracranial meningiomas. Background: While several risk factors for recurrences have been defined, the topographic pattern of meningioma recurrences after surgical resection has been scarcely investigated. The possibility of theoretically predicting the site of recurrence not only allows us to better understand the pathogenetic bases of the disease and consequently to drive the development of new targeted therapies, but also guides the decision-making process for treatment strategies and tailored follow-ups to decrease/prevent recurrence. Methods: The authors performed a comprehensive and detailed systematic literature review of the EMBASE and MEDLINE electronic online databases regarding the topographic pattern of recurrence after surgical treatment for intracranial meningiomas. Demographics and histopathological, neuroradiological and treatment data, pertinent to the topography of recurrences, as well as time to recurrences, were extracted and analyzed. Results: Four studies, including 164 cases of recurrences according to the inclusion criteria, were identified. All studies consider the possibility of recurrence at the previous dural site; three out of four, which are the most recent, consider 1 cm outside the previous dural margin to be the main limit to distinguish recurrences closer to the previous site from those more distant. Recurrences mainly occur within or close to the surgical bed; higher values of proliferation index are associated with recurrences close to the original site rather than within it. Conclusions: Further studies, including genomic characterization of different patterns of recurrence, will better clarify the main features affecting the topography of recurrences. A comparison between topographic classifications of intracranial meningioma recurrences after surgery and after radiation treatment could provide further interesting information. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Melanoma in Pregnancy—Diagnosis, Treatment, and Consequences for Fetal Development and the Maintenance of Pregnancy.
- Author
-
Pelczar, Patrycja, Kosteczko, Pola, Wieczorek, Ewelina, Kwieciński, Maciej, Kozłowska, Aleksandra, and Gil-Kulik, Paulina
- Subjects
MELANOMA treatment ,MELANOMA prognosis ,MELANOMA diagnosis ,CANCER ,MELANOMA ,CANCER relapse ,RADIOTHERAPY ,SENTINEL lymph nodes ,SYSTEMATIC reviews ,MEDLINE ,METASTASIS ,FETAL development ,PREGNANCY complications ,ONLINE information services ,TUMOR classification ,DISEASE risk factors ,PREGNANCY - Abstract
Simple Summary: Pregnancy-associated cancers (PACs) represent a significant clinical problem, due to their possibly delayed diagnosis, limitations of the usage of diagnostic and therapeutic methods, and often the necessity to postpone the administration of optimal treatment to the mother until after delivery to protect the health of the fetus. The purpose of this review is to summarize information on the epidemiology, proper diagnosis, and effective treatment of cutaneous malignant melanoma (CMM) during pregnancy. Moreover, our aim is to point out that there are still many topics related to pregnancy-associated melanoma (PAM) that require further research. The following article can help clinicians systematize the updated facts from various studies and case-reports as well as advise them that an interdisciplinary approach combined with broad knowledge from different fields of medicine is crucial in the treatment of PAM. Cutaneous malignant melanoma is one of the most common neoplasms among pregnancy-associated cancers (PACs). Risk factors include excessive exposure to ultraviolet radiation, the presence of benign and dysplastic nevi, and a patient or family history of melanoma. Self-examination and careful inspection of nevi are crucial, especially in the context of their progression over time. Physiological changes that occur during pregnancy, such as the darkening and enlargement of the nevi, delay the diagnosis of CMM. In the fetus, metastases are very rare, and if they do occur, they concern the placenta or fetal tissues. The choice of treatment is influenced by the cancer stage, symptoms, the time of termination of pregnancy, and the patient's decision. Essential procedures which are safe for the fetus are diagnostic biopsy, ultrasound, and the therapeutic excision of the lesion and the affected lymph nodes. Other imaging methods can be used with a safe radiation dose limit of 100 mGy. Immunotherapy and targeted treatments must be carefully considered, because of their possible adverse effects on the fetus. An interdisciplinary approach to the problem of melanoma during pregnancy is necessary, involving doctors of various specialties. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Navigating Intraductal Papillary Mucinous Neoplasm Management through Fukuoka Consensus vs. European Evidence-Based Guidelines on Pancreatic Cystic Neoplasms—A Study on Two European Centers.
- Author
-
Djordjevic, Vladimir, Knezevic, Djordje, Trotovsek, Blaz, Tomazic, Ales, Petric, Miha, Hadzialjevic, Benjamin, Grubor, Nikica, and Djokic, Mihajlo
- Subjects
TUMOR diagnosis ,TUMOR surgery ,MEDICAL protocols ,PREDICTIVE tests ,JAUNDICE ,RETROSPECTIVE studies ,ENDOSCOPIC ultrasonography ,TREATMENT effectiveness ,PANCREATIC tumors ,PARADIGMS (Social sciences) ,HEALTH facilities ,COMPARATIVE studies ,TUMOR classification ,TUMOR antigens ,SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: This research delves into the realm of pancreatic cystic neoplasms (PCNs), specifically focusing on a subtype with a high malignancy potential that is known as intraductal papillary mucinous neoplasms (IPMNs). By analyzing data from 113 patients across two European medical centers, this study assesses the effectiveness of two key guidelines, the Fukuoka consensus guidelines and the European evidence-based guidelines, in diagnosing severe disease stages in IPMNs. The findings reveal comparable diagnostic accuracies between the guidelines, highlighting the importance of personalized patient care and the potential indicators for surgical intervention. This study underscores the need for continuous research to refine these guidelines to improve patient outcomes and deepen our understanding of PCNs. Through this research, the authors seek to contribute to more accurate diagnosis and treatment strategies, ultimately influencing the broader medical community's approach to managing these complex cystic formations in the pancreas. This study addresses the critical need for the accurate diagnosis and management of intraductal papillary mucinous neoplasms (IPMNs), which are pancreatic cystic neoplasm types holding a substantial potential for malignancy. It evaluates the diagnostic effectiveness of the Fukuoka consensus guidelines and the European evidence-based guidelines in detecting high-grade dysplasia/invasive carcinoma in IPMNs, utilizing a retrospective analysis of 113 patients from two European medical centers. The methods include a comparative analysis of clinical, radiological, and endoscopic ultrasonography data, alongside an assessment of guideline-driven diagnostic performance. The results demonstrate that both guidelines offer similar accuracy in identifying severe disease stages in IPMNs, with certain clinical markers—such as jaundice, solid mass presence, and an increase in CA 19-9 levels—being pivotal in predicting the need for surgical intervention. This study concludes that while both guidelines provide valuable frameworks for IPMN management, there is an inherent need for further research to refine these protocols and improve patient-specific treatment strategies. This research contributes to the ongoing discourse on optimizing diagnostic and treatment paradigms for pancreatic cystic neoplasms, aiming to enhance clinical outcomes and patient care in this challenging medical field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Closing the RCT Gap—A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients.
- Author
-
Doerr, Fabian, Stange, Sebastian, Salamon, Sophie, Grapatsas, Konstantinos, Baldes, Natalie, Michel, Maximilian, Menghesha, Hruy, Schlachtenberger, Georg, Heldwein, Matthias B., Hagmeyer, Lars, Wolf, Jürgen, Roessner, Eric D., Wahlers, Thorsten, Schuler, Martin, Hekmat, Khosro, and Bölükbas, Servet
- Subjects
TREATMENT of lung tumors ,META-analysis ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,LUNG tumors ,INFERENTIAL statistics ,SMALL cell carcinoma ,TUMOR classification ,SURVIVAL analysis (Biometry) ,REGRESSION analysis - Abstract
Simple Summary: Despite guidelines recommending surgery as part of treatment for stage I small cell lung cancer (SCLC), its application remains inconsistent, and its role in stages II and III is under debate. In absence of current randomized control trials this meta-analysis compared surgery to non-surgical treatment for stages I to III SCLC. After a systematic review, ten studies with a total of 95,323 patients were analyzed. The analysis found no significant differences in patient characteristics between the surgery and non-surgery groups. The 5-year survival rate for resected patients was significantly higher compared to non-surgically treated patients. This finding was valid also for patients in stages II and III. Surgery might significantly improve survival in SCLC patients and should be considered in treatment planning even in higher stages. Introduction: Despite clear guideline recommendations, surgery is not consistently carried out as part of multimodal therapy in stage I small cell lung cancer (SCLC) patients. The role of surgery in stages II and III is even more controversial. In the absence of current randomized control trials (RCT), we performed a meta-analysis comparing surgery versus non-surgical treatment in stage I to III SCLC patients. Methods: A systematic review of the literature was conducted on 1 July 2023, focusing on studies pertaining to the impact of surgery on small cell lung cancer (SCLC). These studies were evaluated using the ROBINS-I tool. Statistical analyses, including I² tests, Q-statistics, DerSimonian-Laird tests, and Egger regression, were performed to assess the data. In addition, 5-year survival rates were analyzed. The meta-analysis was conducted according to PRISMA standards. Results: Among the 6826 records identified, 10 original studies encompassing a collective cohort of 95,323 patients were incorporated into this meta-analysis. Heterogeneity was observed across the included studies, with no discernible indication of publication bias. Analysis of patient characteristics revealed no significant differences between the two groups (p-value > 0.05). The 5-year survival rates in a combined analysis of patients in stages I–III were 39.6 ± 15.3% for the 'surgery group' and 16.7 ± 12.7% for the 'non-surgery group' (p-value < 0.0001). SCLC patients in stages II and III treated outside the guideline with surgery had a significantly better 5-year survival compared to non-surgery controls (36.3 ± 20.2% vs. 20.2 ± 17.0%; p-value = 0.043). Conclusions: In the absence of current RCTs, this meta-analysis provides robust suggestions that surgery might significantly improve survival in all SCLC stages. Non-surgical therapy could lead to a shortening of life. The feasibility of surgery in non-metastatic SCLC should always be evaluated as part of a multimodal treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Correlation of pN Stage and Hypoechogenicity with Tumour Encapsulation and Vascular Invasion in Thyroid Cancer (TC): A Comprehensive Analysis and Clinical Outcomes.
- Author
-
Jurkiewicz, Krzysztof, Miciak, Michał, Biernat, Szymon, Wojtczak, Beata, and Kaliszewski, Krzysztof
- Subjects
THYROID gland tumors ,CANCER invasiveness ,RESEARCH funding ,QUESTIONNAIRES ,CANCER patients ,DECISION making in clinical medicine ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,CONNECTIVE tissue tumors ,BLOOD-vessel tumors ,METASTASIS ,MEDICAL records ,ACQUISITION of data ,HISTOLOGICAL techniques ,TUMOR classification ,EVALUATION - Abstract
Simple Summary: This study aimed to explore the relationship of the pN stage of thyroid cancer (TC) and ultrasound hypoechogenicity with encapsulation and vascular invasion. A retrospective study involving 678 TC patients revealed that a greater pN stage was correlated with encapsulation and vascular invasion as well as with positive hypoechogenicity. These findings have significant prognostic and clinical implications for managing TC. Discovering these correlations confirms the importance of the TNM scale in stratifying TC patients based on disease severity. The results suggest that the hypoechoic patterns observed on thyroid ultrasound may serve as indicators of aggressive tumour behaviour and increased invasion risk. This analysis highlights diverse invasion patterns among TC patients, which may have significant clinical implications for diagnostic processes and treatment strategy selection. Further research is necessary to validate these findings and explore new biomarkers and imaging methods to refine TC staging systems and improve TC patient care. In this retrospective study, the relationship between the pN stage of TC and the ultrasound hypoechogenicity of tumour encapsulation and vascular invasion was investigated. The data of a total of 678 TC patients were analysed. The goal of this study was to assess the significance of the pTNM score and preoperative ultrasound features in predicting cancer prognosis and guiding therapeutic decisions in patients with TC. The main research methods included a retrospective analysis of patient data, mainly the pTNM score and presence of tumour encapsulation and vascular invasion obtained from histopathological results and preoperative ultrasound imaging. Patients with well-differentiated TCs (papillary and follicular) were extracted from TC patients to better unify the results because of similar clinical strategies for these TCs. Significant associations were observed between advanced pN stage and the presence of encapsulation and vessel invasion. The majority of pN1a patients exhibited encapsulation (77.71%; p < 0.0001) and vascular invasion (75.30%; p < 0.0001), as did the majority of pN1b patients (100%; p < 0.0001 and 100%; p < 0.0001, respectively). Less than half of the patients with hypoeghogenic patterns presented with encapsulation (43.30%; p < 0.0001) and vascular invasion (43.52%; p < 0.0001), while the vast majority of patients without hypoechogenicity did not present with encapsulation (90.97%; p < 0.0001) or vascular invasion (90.97%; p < 0.0001). Hypoechogenicity was found to be indicative of aggressive tumour behaviour. The results of this study underscore the importance of accurate N staging in TC and suggests the potential use of ultrasound features in predicting tumour behaviour. Further research is needed to confirm these findings and explore additional prognostic markers to streamline TC management strategies and improve patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Systematic Review—Role of MRI in Cervical Cancer Staging.
- Author
-
Chen, Jason, Kitzing, Yu Xuan, and Lo, Glen
- Subjects
MEDICAL information storage & retrieval systems ,LYMPH nodes ,CERVIX uteri tumors ,PELVIS ,VAGINA ,CANCER invasiveness ,MAGNETIC resonance imaging ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,MEDLINE ,METASTASIS ,MEDICAL databases ,BLADDER ,TUMOR classification ,ONLINE information services ,SENSITIVITY & specificity (Statistics) ,RECTUM - Abstract
Simple Summary: Cervical cancer is the fourth most common cancer in women and its staging is classified by the International Federation of Gynecology and Obstetrics staging, which was updated in 2018. This is based on a combination of histopathology, clinical examination and radiographical findings. MRI plays a critical role due to its superior soft tissue resolution. The aim of our systematic review was to assess the diagnostic accuracy of MRI in the staging of cervical cancer. The literature from the last 5 years showed that MRI had a high accuracy and sensitivity in assessing stromal invasion, high accuracy and specificity in assessing pelvic sidewall involvement, and high accuracy, specificity and negative predictive value in assessing bladder and rectal involvement. A systematic review of the diagnostic accuracy of MRI in the staging of cervical cancer was conducted based on the literature from the last 5 years. A literature search was performed in the Cochrane Library, EMBASE, MEDLINE and PubMed databases using the MeSH terms "cervical cancer", "MRI" and "neoplasm staging". A total of 110 studies were identified, of which 8 fit the inclusion criteria. MRI showed adequate accuracy (74–95%) and high sensitivity (92–100%) in assessing stromal invasion. The data for MRI in terms of assessing vaginal and pelvic side wall involvement were wide ranging and inconclusive. In assessing lymph node metastasis, MRI showed an adequate accuracy (73–90%), specificity (75–91%) and NPV (71–96%) but poor sensitivity (52–75%) and PPV (52–75%). MRI showed high accuracy (95%), sensitivity (78–96%), specificity (87–94%), and NPV (98–100%) but poor PPV (27–42%) in detecting bladder involvement. There was a paucity of data on the use of MRI in assessing rectal involvement in cervical cancer. Overall, the literature was heterogenous in the definitions and language used, which reduced the comparability between articles. More research is required into the diagnostic accuracy of MRI in the staging of cervical cancer and there must be increased consistency in the definitions and language used in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.